Author: Wilde, Adriaan Hugo de
Title: Host factors in nidovirus replication
Issue Date: 2013-11-13

References

REFERENCES

1. **Morens, D. M., and A. S. Fauci.** 2013. Emerging Infectious Diseases: Threats to Human Health and Global Stability. PLoS Pathog. **9:**e1003467.
2. **http://www.who.int/topics/emerging_diseases/en/**
3. **http://www.who.int/topics/influenza/en/**
4. **http://www.who.int/hiv/**
5. **http://www.who.int/mediacentre/factsheets/fs164/en/**
6. **Drosten, C., S. Gunther, W. Preiser, S. van der Werf, H. R. Brodt, S. Becker, H. Rabenau, M. Panning**, *et al*. 2003. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. **348:**1967-1976.
7. **Ksiazek, T. G., D. Erdman, C. S. Goldsmith, S. R. Zaki, T. Peret, S. Emery, S. Tong, C. Urbani**, *et al*. 2003. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. **348:**1953-1966.
8. **Kuiken, T., R. A. Fouchier, M. Schutten, G. F. Rimmelzwaan, G. van Amerongen, D. van Riel, J. D. Laman, T. de Jong**, *et al*. 2003. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet **362:**263-270.
9. **http://www.who.int/csr/sars/country/table2004_04_21/**
10. **Keogh-Brown, M. R., and R. D. Smith.** 2008. The economic impact of SARS: how does the reality match the predictions? Health policy **88:**110-120.
11. **Lau, S. K., P. C. Woo, K. S. Li, Y. Huang, H. W. Tsoi, B. H. Wong, S. S. Wong, S. Y. Leung**, *et al*. 2005. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc. Natl. Acad. Sci. USA **102:**14040-14045.
12. **Li, W., Z. Shi, M. Yu, W. Ren, C. Smith, J. H. Epstein, H. Wang, G. Crameri**, *et al*. 2005. Bats are natural reservoirs of SARS-like coronaviruses. Science **310:**676-679.
13. **Li, W., C. Zhang, J. Sui, J. H. Kuhn, M. J. Moore, S. Luo, S. K. Wong, I. C. Huang**, *et al*. 2005. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J. **24:**1634-1643.
14. **de Groot, R. J., S. C. Baker, R. S. Baric, C. S. Brown, C. Drosten, L. Enjuanes, R. A. Fouchier, M. Galiano**, *et al*. 2013. Middle East Respiratory Syndrome Coronavirus (MERS-CoV); Announcement of the Coronavirus Study Group. J. Virol.
15. **Zaki, A. M., S. van Boheemen, T. M. Bestebroer, A. D. Osterhaus, and R. A. Fouchier.** 2012. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. **367:**1814-1820.
16. **van Boheemen, S., M. de Graaf, C. Lauber, T. M. Bestebroer, V. S. Raj, A. M. Zaki, A. D. Osterhaus, B. L. Haagmans**, *et al*. 2012. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio **3:**e00473-00412.
17. **http://www.who.int/csr/don/archive/disease/coronavirus_infections/en/**
18. **Muller, M. A., V. S. Raj, D. Muth, B. Meyer, S. Kallies, S. L. Smits, R. Wollny, T. M. Bestebroer**, *et al*. 2012. Human Coronavirus EMC Does Not Require the SARS-Coronavirus Receptor and Maintains Broad Replicative Capability in Mammalian Cell Lines. MBio **3:**e00515-00512.
19. **van der Hoek, L.** 2007. Human coronaviruses: what do they cause? Antivir. Ther. **12:**651-658.
20. **McIntosh, K., J. H. Dees, W. B. Becker, A. Z. Kapikian, and R. M. Chanock.** 1967. Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. Proc. Natl. Acad. Sci. USA **57:**933-940.

21. **Hamre, D., and J. J. Procknow.** 1966. A new virus isolated from the human respiratory tract. Proc. Soc. Exp. Biol. Med. **121:**190-193.
22. **van der Hoek, L., K. Pyrc, M. F. Jebbink, W. Vermeulen-Oost, R. J. Berkhout, K. C. Wolthers, P. M. Wertheim-van Dillen, J. Kaandorp**, *et al*. 2004. Identification of a new human coronavirus. Nat. Med. **10:**368-373.
23. **Woo, P. C., S. K. Lau, C. M. Chu, K. H. Chan, H. W. Tsoi, Y. Huang, B. H. Wong, R. W. Poon**, *et al*. 2005. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J. Virol. **79:**884-895.
24. **Huynh, J., S. Li, B. Yount, A. Smith, L. Sturges, J. C. Olsen, J. Nagel, J. B. Johnson**, *et al*. 2012. Evidence supporting a zoonotic origin of human coronavirus strain NL63. J. Virol. **86:**12816-12825.
25. **www.promedmail.org**
26. **Snijder, E. J., and M. Kikkert.** 2013. Arteriviruses, p. 859-879. In D. M. Knipe and P. M. Howley (ed.), Fields Virology, 6 ed. Lippincott Williams & Wilkins, Philadelphia, PA.
27. **Holtkamp, D. J., J. B. Kliebenstein, E. J. Neumann, J. J. Zimmerman, H. Rotto, T. K. Yoder, C. Wang, P. Yeske**, *et al*. 2011. Presented at the 2011 International PRRS Symposium, Chicago, Illinois, USA.
28. **Belov, G. A., and F. J. van Kuppeveld.** 2012. (+)RNA viruses rewire cellular pathways to build replication organelles. Current opinion in virology.
29. **Knoops, K., M. Barcena, R. W. Limpens, A. J. Koster, A. M. Mommaas, and E. J. Snijder.** 2012. Ultrastructural characterization of arterivirus replication structures: reshaping the endoplasmic reticulum to accommodate viral RNA synthesis. J. Virol. **86:**2474-2487.
30. **Knoops, K., M. Kikkert, S. H. Worm, J. C. Zevenhoven-Dobbe, Y. van der Meer, A. J. Koster, A. M. Mommaas, and E. J. Snijder.** 2008. SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum. PLoS Biol. **6:**e226.
31. **Gosert, R., A. Kanjanahaluethai, D. Egger, K. Bienz, and S. C. Baker.** 2002. RNA replication of mouse hepatitis virus takes place at double-membrane vesicles. J. Virol. **76:**3697-3708.
32. **van der Meer, Y., E. J. Snijder, J. C. Dobbe, S. Schleich, M. R. Denison, W. J. Spaan, and J. Krijnse Locker.** 1999. Localization of mouse hepatitis virus nonstructural proteins and RNA synthesis indicates a role for late endosomes in viral replication. J. Virol. **73:**7641-7657.
33. **van der Meer, Y., H. van Tol, J. Krijnse Locker, and E. J. Snijder.** 1998. ORF1a-encoded replicase subunits are involved in the membrane association of the arterivirus replication complex. J. Virol. **72:**6689-6698.
34. **Brockway, S. M., C. T. Clay, X. T. Lu, and M. R. Denison.** 2003. Characterization of the expression, intracellular localization, and replication complex association of the putative mouse hepatitis virus RNA-dependent RNA polymerase. J. Virol. **77:**10515-10527.
35. **Stertz, S., M. Reichelt, M. Spiegel, T. Kuri, L. Martinez-Sobrido, A. Garcia-Sastre, F. Weber, and G. Kochs.** 2007. The intracellular sites of early replication and budding of SARS-coronavirus. Virology **361:**304-315.
36. **Ulasli, M., M. H. Verheije, C. A. de Haan, and F. Reggiori.** 2010. Qualitative and quantitative ultrastructural analysis of the membrane rearrangements induced by coronavirus. Cell. Microbiol. **12:**844-861.
37. **Gorbalenya, A. E., L. Enjuanes, J. Ziebuhr, and E. J. Snijder.** 2006. Nidovirales: evolving the largest RNA virus genome. Virus Res. **117:**17-37.

38. **Nga, P. T., C. Parquet Mdel, C. Lauber, M. Parida, T. Nabeshima, F. Yu, N. T. Thuy, S. Inoue**, *et al*. 2011. Discovery of the first insect nidovirus, a missing evolutionary link in the emergence of the largest RNA virus genomes. PLoS Pathog. **7:**e1002215.
39. **Sawicki, S. G., and D. L. Sawicki.** 1995. Coronaviruses use discontinuous extension for synthesis of subgenome-length negative strands. Adv. Exp. Med. Biol. **380:**499-506.
40. **Pasternak, A. O., W. J. Spaan, and E. J. Snijder.** 2006. Nidovirus transcription: how to make sense...? J. Gen. Virol. **87:**1403-1421.
41. **Snijder, E. J., S. Siddell, and A. E. Gorbalenya.** 2005. The order Nidovirales, p. 390–404. In B. W. Mahy and V. ter Meulen (ed.), Topley and Wilson's Microbiology and Microbial Infections: Virology Volume. Hodder Arnold, London.
42. **den Boon, J. A., E. J. Snijder, E. D. Chirnside, A. A. de Vries, M. C. Horzinek, and W. J. Spaan.** 1991. Equine arteritis virus is not a togavirus but belongs to the coronaviruslike superfamily. J. Virol. **65:**2910-2920.
43. **Brierley, I., and F. J. Dos Ramos.** 2006. Programmed ribosomal frameshifting in HIV-1 and the SARS-CoV. Virus Res. **119:**29-42.
44. **Brierley, I., P. Digard, and S. C. Inglis.** 1989. Characterization of an efficient coronavirus ribosomal frameshifting signal: requirement for an RNA pseudoknot. Cell **57:**537-547.
45. **Van Hemert, M. J., and E. J. Snijder.** 2008. The Arterivirus Replicase. In S. Perlman, T. Gallagher, and E. J. Snijder (ed.), Nidoviruses. ASM Press.
46. **Ziebuhr, J.** 2006. The coronavirus replicase: insights into a sophisticated enzyme machinery. Adv. Exp. Med. Biol. **581:**3-11.
47. **Fang, Y., and E. J. Snijder.** 2010. The PRRSV replicase: exploring the multifunctionality of an intriguing set of nonstructural proteins. Virus Res. **154:**61-76.
48. **Lauber, C., J. Ziebuhr, S. Junglen, C. Drosten, F. Zirkel, P. T. Nga, K. Morita, E. J. Snijder, and A. E. Gorbalenya.** 2012. Mesoniviridae: a proposed new family in the order Nidovirales formed by a single species of mosquito-borne viruses. Arch. Virol. **157:**1623-1628.
49. **Ulferts, R., and J. Ziebuhr.** 2011. Nidovirus ribonucleases: Structures and functions in viral replication. RNA Biol. **8:**295-304.
50. **Denison, M. R., R. L. Graham, E. F. Donaldson, L. D. Eckerle, and R. S. Baric.** 2011. Coronaviruses: an RNA proofreading machine regulates replication fidelity and diversity. RNA Biol. **8:**270-279.
51. **Bouvet, M., I. Imbert, L. Subissi, L. Gluais, B. Canard, and E. Decroly.** 2012. RNA 3′-end mismatch excision by the severe acute respiratory syndrome coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complex. Proc. Natl. Acad. Sci. USA **109:**9372-9377.
52. **van Hemert, M. J., A. H. de Wilde, A. E. Gorbalenya, and E. J. Snijder.** 2008. The *in vitro* RNA synthesizing activity of the isolated arterivirus replication/transcription complex is dependent on a host factor. J. Biol. Chem. **283:**16525-16536.
53. **van Hemert, M. J., S. H. van den Worm, K. Knoops, A. M. Mommaas, A. E. Gorbalenya, and E. J. Snijder.** 2008. SARS-coronavirus replication/transcription complexes are membrane-protected and need a host factor for activity *in vitro*. PLoS Pathog. **4:**e1000054.
54. **Prentice, E., W. G. Jerome, T. Yoshimori, N. Mizushima, and M. R. Denison.** 2004. Coronavirus replication complex formation utilizes components of cellular autophagy. J. Biol. Chem. **279:**10136-10141.
55. **Reggiori, F., I. Monastyrska, M. H. Verheije, T. Cali, M. Ulasli, S. Bianchi, R. Bernasconi, C. A. de Haan, and M. Molinari.** 2010. Coronaviruses Hijack the LC3-I-positive EDEMosomes, ER-derived vesicles exporting short-lived ERAD regulators, for replication. Cell Host Microbe **7:**500-508.

56. **Miller, S., and J. Krijnse-Locker.** 2008. Modification of intracellular membrane structures for virus replication. Nat. Rev. Microbiol. **6:**363-374.

57. **Krijnse-Locker, J., M. Ericsson, P. J. Rottier, and G. Griffiths.** 1994. Characterization of the budding compartment of mouse hepatitis virus: evidence that transport from the RER to the Golgi complex requires only one vesicular transport step. J. Cell. Biol. **124:**55-70.

58. **Wieringa, R., A. A. de Vries, J. van der Meulen, G. J. Godeke, J. J. Onderwater, H. van Tol, H. K. Koerten, A. M. Mommaas**, *et al*. 2004. Structural protein requirements in equine arteritis virus assembly. J. Virol. **78:**13019-13027.

59. **Griffiths, G., and P. Rottier.** 1992. Cell biology of viruses that assemble along the biosynthetic pathway. Semin. Cell. Biol. **3:**367-381.

60. **Nagy, P. D., and J. Pogany.** 2012. The dependence of viral RNA replication on co-opted host factors. Nat. Rev. Microbiol. **10:**137-149.

61. **Li, Z., and P. D. Nagy.** 2011. Diverse roles of host RNA binding proteins in RNA virus replication. RNA Biol. **8:**305-315.

62. **Ahlquist, P., A. O. Noueiry, W. M. Lee, D. B. Kushner, and B. T. Dye.** 2003. Host factors in positive-strand RNA virus genome replication. J. Virol. **77:**8181-8186.

63. **Moriishi, K., and Y. Matsuura.** 2007. Host factors involved in the replication of hepatitis C virus. Rev. Med. Virol. **17:**343-354.

64. **Watanabe, T., S. Watanabe, and Y. Kawaoka.** 2010. Cellular networks involved in the influenza virus life cycle. Cell Host Microbe **7:**427-439.

65. **Zhong, Y., Y. W. Tan, and D. X. Liu.** 2012. Recent progress in studies of arterivirus- and coronavirus-host interactions. Viruses **4:**980-1010.

66. **Walsh, D., and I. Mohr.** 2011. Viral subversion of the host protein synthesis machinery. Nat. Rev. Microbiol. **9:**860-875.

67. **Jackson, R. J., C. U. Hellen, and T. V. Pestova.** 2010. The mechanism of eukaryotic translation initiation and principles of its regulation. Nat. Rev. Mol. Cell Biol. **11:**113-127.

68. **Dauber, B., and T. Wolff.** 2009. Activation of the Antiviral Kinase PKR and Viral Countermeasures. Viruses **1:**523-544.

69. **Wang, X., Y. Liao, P. L. Yap, K. J. Png, J. P. Tam, and D. X. Liu.** 2009. Inhibition of protein kinase R activation and upregulation of GADD34 expression play a synergistic role in facilitating coronavirus replication by maintaining de novo protein synthesis in virus-infected cells. J. Virol. **83:**12462-12472.

70. **Cruz, J. L., I. Sola, M. Becares, B. Alberca, J. Plana, L. Enjuanes, and S. Zuniga.** 2011. Coronavirus gene 7 counteracts host defenses and modulates virus virulence. PLoS Pathog. **7:**e1002090.

71. **Xiao, H., L. H. Xu, Y. Yamada, and D. X. Liu.** 2008. Coronavirus spike protein inhibits host cell translation by interaction with eIF3f. PLoS One **3:**e1494.

72. **Lokugamage, K. G., K. Narayanan, C. Huang, and S. Makino.** 2012. SARS coronavirus nsp1 protein is a novel eukaryotic translation inhibitor that represses multiple steps of translation initiation. J. Virol.

73. **Kamitani, W., C. Huang, K. Narayanan, K. G. Lokugamage, and S. Makino.** 2009. A two-pronged strategy to suppress host protein synthesis by SARS coronavirus Nsp1 protein. Nat. Struct. Mol. Biol. **16:**1134-1140.

74. **Kamitani, W., K. Narayanan, C. Huang, K. Lokugamage, T. Ikegami, N. Ito, H. Kubo, and S. Makino.** 2006. Severe acute respiratory syndrome coronavirus nsp1 protein suppresses host gene expression by promoting host mRNA degradation. Proc. Natl. Acad. Sci. USA **103:**12885-12890.

75. **Mackenzie, J.** 2005. Wrapping things up about virus RNA replication. Traffic **6:**967-977.

76. **Welsch, S., S. Miller, I. Romero-Brey, A. Merz, C. K. Bleck, P. Walther, S. D. Fuller, C. Antony**, *et al*. 2009. Composition and three-dimensional architecture of the dengue virus replication and assembly sites. Cell Host Microbe **5:**365-375.

77. **Gillespie, L. K., A. Hoenen, G. Morgan, and J. M. Mackenzie.** 2010. The endoplasmic reticulum provides the membrane platform for biogenesis of the flavivirus replication complex. J. Virol. **84:**10438-10447.

78. **Kopek, B. G., G. Perkins, D. J. Miller, M. H. Ellisman, and P. Ahlquist.** 2007. Three-dimensional analysis of a viral RNA replication complex reveals a virus-induced mini-organelle. PLoS Biol. **5:**e220.

79. **Spuul, P., G. Balistreri, L. Kaariainen, and T. Ahola.** 2010. Phosphatidylinositol 3-kinase-, actin-, and microtubule-dependent transport of Semliki Forest Virus replication complexes from the plasma membrane to modified lysosomes. J. Virol. **84:**7543-7557.

80. **Belov, G. A., V. Nair, B. T. Hansen, F. H. Hoyt, E. R. Fischer, and E. Ehrenfeld.** 2012. Complex dynamic development of poliovirus membranous replication complexes. J. Virol. **86:**302-312.

81. **Romero-Brey, I., A. Merz, A. Chiramel, J. Y. Lee, P. Chlanda, U. Haselman, R. Santarella-Mellwig, A. Habermann**, *et al*. 2012. Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication. PLoS Pathog. **8:**e1003056.

82. **Norbury, C., and P. Nurse.** 1992. Animal cell cycles and their control. Annu. Rev. Biochem. **61:**441-470.

83. **Nigg, E. A.** 1995. Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle. BioEssays : news and reviews in molecular, cellular and developmental biology **17:**471-480.

84. **Davy, C., and J. Doorbar.** 2007. G2/M cell cycle arrest in the life cycle of viruses. Virology **368:**219-226.

85. **Xu, L. H., M. Huang, S. G. Fang, and D. X. Liu.** 2011. Coronavirus infection induces DNA replication stress partly through interaction of its nonstructural protein 13 with the p125 subunit of DNA polymerase delta. J. Biol. Chem. **286:**39546-39559.

86. **Xu, L., S. Khadijah, S. Fang, L. Wang, F. P. Tay, and D. X. Liu.** 2010. The cellular RNA helicase DDX1 interacts with coronavirus nonstructural protein 14 and enhances viral replication. J. Virol. **84:**8571-8583.

87. **Bhardwaj, K., P. Liu, J. L. Leibowitz, and C. C. Kao.** 2012. The coronavirus endoribonuclease Nsp15 interacts with retinoblastoma tumor suppressor protein. J. Virol. **86:**4294-4304.

88. **Chen, C. J., and S. Makino.** 2004. Murine coronavirus replication induces cell cycle arrest in G0/G1 phase. J. Virol. **78:**5658-5669.

89. **Chen, C. J., K. Sugiyama, H. Kubo, C. Huang, and S. Makino.** 2004. Murine coronavirus nonstructural protein p28 arrests cell cycle in G0/G1 phase. J. Virol. **78:**10410-10419.

90. **Jensen, S., and A. R. Thomsen.** 2012. Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion. J. Virol. **86:**2900-2910.

91. **Schoggins, J. W., and C. M. Rice.** 2011. Interferon-stimulated genes and their antiviral effector functions. Current opinion in virology **1:**519-525.

92. **Jiang, X., and Z. J. Chen.** 2012. The role of ubiquitylation in immune defence and pathogen evasion. Nat. Rev. Immunol. **12:**35-48.

93. **Versteeg, G. A., and A. Garcia-Sastre.** 2010. Viral tricks to grid-lock the type I interferon system. Curr. Opin. Microbiol. **13:**508-516.

94. **Barretto, N., D. Jukneliene, K. Ratia, Z. Chen, A. D. Mesecar, and S. C. Baker.** 2005. The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity. J. Virol. **79:**15189-15198.

95. **Zheng, D., G. Chen, B. Guo, G. Cheng, and H. Tang.** 2008. PLP2, a potent deubiquitinase from murine hepatitis virus, strongly inhibits cellular type I interferon production. Cell Res. **18:**1105-1113.

96. **Chen, Z., Y. Wang, K. Ratia, A. D. Mesecar, K. D. Wilkinson, and S. C. Baker.** 2007. Proteolytic processing and deubiquitinating activity of papain-like proteases of human coronavirus NL63. J. Virol. **81:**6007-6018.

97. **Lindner, H. A., N. Fotouhi-Ardakani, V. Lytvyn, P. Lachance, T. Sulea, and R. Menard.** 2005. The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme. J. Virol. **79:**15199-15208.

98. **Wojdyla, J. A., I. Manolaridis, P. B. van Kasteren, M. Kikkert, E. J. Snijder, A. E. Gorbalenya, and P. A. Tucker.** 2010. Papain-like protease 1 from transmissible gastroenteritis virus: crystal structure and enzymatic activity toward viral and cellular substrates. J. Virol. **84:**10063-10073.

99. **Clementz, M. A., Z. Chen, B. S. Banach, Y. Wang, L. Sun, K. Ratia, Y. M. Baez-Santos, J. Wang**, *et al*. 2010. Deubiquitinating and interferon antagonism activities of coronavirus papain-like proteases. J. Virol. **84:**4619-4629.

100. **Sun, Z., Z. Chen, S. R. Lawson, and Y. Fang.** 2010. The cysteine protease domain of porcine reproductive and respiratory syndrome virus nonstructural protein 2 possesses deubiquitinating and interferon antagonism functions. J. Virol. **84:**7832-7846.

101. **van Kasteren, P. B., C. Beugeling, D. K. Ninaber, N. Frias-Staheli, S. van Boheemen, A. Garcia-Sastre, E. J. Snijder, and M. Kikkert.** 2012. Arterivirus and nairovirus ovarian tumor domain-containing Deubiquitinases target activated RIG-I to control innate immune signaling. J. Virol. **86:**773-785.

102. **van Kasteren, P. B., B. A. Bailey-Elkin, T. W. James, D. K. Ninaber, C. Beugeling, M. Khajehpour, E. J. Snijder, B. L. Mark, and M. Kikkert.** 2013. Deubiquitinase function of arterivirus papain-like protease 2 suppresses the innate immune response in infected host cells. Proc. Natl. Acad. Sci. USA **110:**E838-847.

103. **Totura, A. L., and R. S. Baric.** 2012. SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon. Current opinion in virology **2:**264-275.

104. **Wathelet, M. G., M. Orr, M. B. Frieman, and R. S. Baric.** 2007. Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain. J. Virol. **81:**11620-11633.

105. **Frieman, M., B. Yount, M. Heise, S. A. Kopecky-Bromberg, P. Palese, and R. S. Baric.** 2007. Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane. J. Virol. **81:**9812-9824.

106. **Kopecky-Bromberg, S. A., L. Martinez-Sobrido, M. Frieman, R. A. Baric, and P. Palese.** 2007. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J. Virol. **81:**548-557.

107. **Patel, D., Y. Nan, M. Shen, K. Ritthipichai, X. Zhu, and Y. J. Zhang.** 2010. Porcine reproductive and respiratory syndrome virus inhibits type I interferon signaling by blocking STAT1/STAT2 nuclear translocation. J. Virol. **84:**11045-11055.

108. **Wang, R., Y. Nan, Y. Yu, and Y. J. Zhang.** 2013. Porcine reproductive and respiratory syndrome virus Nsp1beta inhibits interferon-activated JAK/STAT signal transduction by inducing karyopherin-alpha1 degradation. J. Virol. **87:**5219-5228.

109. **Zhou, P., H. Li, H. Wang, L. F. Wang, and Z. Shi.** 2012. Bat severe acute respiratory syndrome-like coronavirus ORF3b homologues display different interferon antagonist activities. J. Gen. Virol. **93:**275-281.

110. **Frieman, M., K. Ratia, R. E. Johnston, A. D. Mesecar, and R. S. Baric.** 2009. Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling. J. Virol. **83:**6689-6705.

111. **Wang, G., G. Chen, D. Zheng, G. Cheng, and H. Tang.** 2011. PLP2 of mouse hepatitis virus A59 (MHV-A59) targets TBK1 to negatively regulate cellular type I interferon signaling pathway. PLoS One **6:**e17192.

112. **Siu, K. L., K. H. Kok, M. H. Ng, V. K. Poon, K. Y. Yuen, B. J. Zheng, and D. Y. Jin.** 2009. Severe acute respiratory syndrome coronavirus M protein inhibits type I interferon production by impeding the formation of TRAF3.TANK.TBK1/IKKepsilon complex. J. Biol. Chem. **284:**16202-16209.

113. **Devaraj, S. G., N. Wang, Z. Chen, M. Tseng, N. Barretto, R. Lin, C. J. Peters, C. T. Tseng**, *et al*. 2007. Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus. J. Biol. Chem. **282:**32208-32221.

114. **Enjuanes, L., F. Almazan, I. Sola, S. Zuniga, E. Alvarez, J. Reguera, and C. Capiscol.** 2006. Biochemical aspects of coronavirus replication. Adv. Exp. Med. Biol. **581:**13-24.

115. **Spagnolo, J. F., and B. G. Hogue.** 2000. Host protein interactions with the 3′ end of bovine coronavirus RNA and the requirement of the poly(A) tail for coronavirus defective genome replication. J. Virol. **74:**5053-5065.

116. **Galan, C., I. Sola, A. Nogales, B. Thomas, A. Akoulitchev, L. Enjuanes, and F. Almazan.** 2009. Host cell proteins interacting with the 3′ end of TGEV coronavirus genome influence virus replication. Virology **391:**304-314.

117. **Wang, X., J. Bai, L. Zhang, X. Wang, Y. Li, and P. Jiang.** 2012. Poly(A)-binding protein interacts with the nucleocapsid protein of porcine reproductive and respiratory syndrome virus and participates in viral replication. Antiviral Res. **96:**315-323.

118. **Beura, L. K., P. X. Dinh, F. A. Osorio, and A. K. Pattnaik.** 2011. Cellular poly(c) binding proteins 1 and 2 interact with porcine reproductive and respiratory syndrome virus nonstructural protein 1beta and support viral replication. J. Virol. **85:**12939-12949.

119. **Wang, Y., and X. Zhang.** 1999. The nucleocapsid protein of coronavirus mouse hepatitis virus interacts with the cellular heterogeneous nuclear ribonucleoprotein A1 *in vitro* and *in vivo*. Virology **265:**96-109.

120. **Luo, H., Q. Chen, J. Chen, K. Chen, X. Shen, and H. Jiang.** 2005. The nucleocapsid protein of SARS coronavirus has a high binding affinity to the human cellular heterogeneous nuclear ribonucleoprotein A1. FEBS Lett. **579:**2623-2628.

121. **Li, H. P., X. Zhang, R. Duncan, L. Comai, and M. M. Lai.** 1997. Heterogeneous nuclear ribonucleoprotein A1 binds to the transcription-regulatory region of mouse hepatitis virus RNA. Proc. Natl. Acad. Sci. USA **94:**9544-9549.

122. **Huang, P., and M. M. Lai.** 2001. Heterogeneous nuclear ribonucleoprotein a1 binds to the 3′-untranslated region and mediates potential 5′-3′-end cross talks of mouse hepatitis virus RNA. J. Virol. **75:**5009-5017.

123. **Jourdan, S. S., F. Osorio, and J. A. Hiscox.** 2012. An interactome map of the nucleocapsid protein from a highly pathogenic North American porcine reproductive and respiratory syndrome virus strain generated using SILAC-based quantitative proteomics. Proteomics **12:**1015-1023.

124. **Tijms, M. A., and E. J. Snijder.** 2003. Equine arteritis virus non-structural protein 1, an essential factor for viral subgenomic mRNA synthesis, interacts with the cellular transcription co-factor p100. J. Gen. Virol. **84:**2317-2322.

125. **Kwak, H., M. W. Park, and S. Jeong.** 2011. Annexin A2 binds RNA and reduces the frameshifting efficiency of infectious bronchitis virus. PLoS One **6:**e24067.

126. **Nanda, S. K., and J. L. Leibowitz.** 2001. Mitochondrial aconitase binds to the 3′ untranslated region of the mouse hepatitis virus genome. J. Virol. **75:**3352-3362.

127. **Tan, Y. W., W. Hong, and D. X. Liu.** 2012. Binding of the 5′-untranslated region of coronavirus RNA to zinc finger CCHC-type and RNA-binding motif 1 enhances viral replication and transcription. Nucleic Acids Res. **40:**5065-5077.

128. **Maines, T. R., M. Young, N. N. Dinh, and M. A. Brinton.** 2005. Two cellular proteins that interact with a stem loop in the simian hemorrhagic fever virus 3′(+)NCR RNA. Virus Res. **109:**109-124.

129. **Li, H. P., P. Huang, S. Park, and M. M. Lai.** 1999. Polypyrimidine tract-binding protein binds to the leader RNA of mouse hepatitis virus and serves as a regulator of viral transcription. J. Virol. **73:**772-777.

130. **Kellam, P.** 2006. Attacking pathogens through their hosts. Genome Biol. **7:**201.

131. **Schwegmann, A., and F. Brombacher.** 2008. Host-directed drug targeting of factors hijacked by pathogens. Sci. Signal **1:**re8.

132. **Yeh, K. M., T. S. Chiueh, L. K. Siu, J. C. Lin, P. K. Chan, M. Y. Peng, H. L. Wan, J. H. Chen**, *et al*. 2005. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J. Antimicrob. Chemother. **56:**919-922.

133. **Cheng, Y., R. Wong, Y. O. Soo, W. S. Wong, C. K. Lee, M. H. Ng, P. Chan, K. C. Wong**, *et al*. 2005. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur. J. Clin. Microbiol. Infect. Dis. **24:**44-46.

134. **Tong, T. R.** 2009. Therapies for coronaviruses. Part I of II -- viral entry inhibitors. Expert Opin. Ther. Pat. **19:**357-367.

135. **van den Brink, E. N., J. Ter Meulen, F. Cox, M. A. Jongeneelen, A. Thijsse, M. Throsby, W. E. Marissen, P. M. Rood**, *et al*. 2005. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus. J. Virol. **79:**1635-1644.

136. **ter Meulen, J., A. B. Bakker, E. N. van den Brink, G. J. Weverling, B. E. Martina, B. L. Haagmans, T. Kuiken, J. de Kruif**, *et al*. 2004. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet **363:**2139-2141.

137. **ter Meulen, J., E. N. van den Brink, L. L. Poon, W. E. Marissen, C. S. Leung, F. Cox, C. Y. Cheung, A. Q. Bakker**, *et al*. 2006. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med. **3:**e237.

138. **Takano, T., Y. Katoh, T. Doki, and T. Hohdatsu.** 2013. Effect of chloroquine on feline infectious peritonitis virus infection *in vitro* and *in vivo*. Antiviral Res. **99:**100-107.

139. **Keyaerts, E., S. Li, L. Vijgen, E. Rysman, J. Verbeeck, M. Van Ranst, and P. Maes.** 2009. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob. Agents Chemother. **53:**3416-3421.

140. **Krzystyniak, K., and J. M. Dupuy.** 1984. Entry of mouse hepatitis virus 3 into cells. J. Gen. Virol. **65 (Pt 1):**227-231.

141. **Payne, H. R., J. Storz, and W. G. Henk.** 1990. Initial events in bovine coronavirus infection: analysis through immunogold probes and lysosomotropic inhibitors. Arch. Virol. **114:**175-189.

142. **Kreutz, L. C., and M. R. Ackermann.** 1996. Porcine reproductive and respiratory syndrome virus enters cells through a low pH-dependent endocytic pathway. Virus Res. **42:**137-147.

143. **Kono, M., K. Tatsumi, A. M. Imai, K. Saito, T. Kuriyama, and H. Shirasawa.** 2008. Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK. Antiviral Res. **77:**150-152.

144. **Keyaerts, E., L. Vijgen, P. Maes, J. Neyts, and M. Van Ranst.** 2004. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem. Biophys. Res. Commun. **323:**264-268.

145. **Du, L., Y. He, Y. Zhou, S. Liu, B. J. Zheng, and S. Jiang.** 2009. The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat. Rev. Microbiol. **7:**226-236.

146. **Fernandez-Montero, J. V., P. Barreiro, and V. Soriano.** 2009. HIV protease inhibitors: recent clinical trials and recommendations on use. Expert Opin. Pharmacother. **10:**1615-1629.

147. **Clark, V. C., J. A. Peter, and D. R. Nelson.** 2013. New therapeutic strategies in HCV: second-generation protease inhibitors. Liver Int. **33 Suppl 1:**80-84.

148. **Yang, H., W. Xie, X. Xue, K. Yang, J. Ma, W. Liang, Q. Zhao, Z. Zhou**, *et al*. 2005. Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol. **3:**e324.

149. **Ghosh, A. K., J. Takayama, K. V. Rao, K. Ratia, R. Chaudhuri, D. C. Mulhearn, H. Lee, D. B. Nichols**, *et al*. 2010. Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biological evaluation. J. Med. Chem. **53:**4968-4979.

150. **Hsu, J. T., C. J. Kuo, H. P. Hsieh, Y. C. Wang, K. K. Huang, C. P. Lin, P. F. Huang, X. Chen, and P. H. Liang.** 2004. Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV. FEBS Lett. **574:**116-120.

151. **Kuo, C. J., H. G. Liu, Y. K. Lo, C. M. Seong, K. I. Lee, Y. S. Jung, and P. H. Liang.** 2009. Individual and common inhibitors of coronavirus and picornavirus main proteases. FEBS Lett. **583:**549-555.

152. **Wu, C. Y., J. T. Jan, S. H. Ma, C. J. Kuo, H. F. Juan, Y. S. Cheng, H. H. Hsu, H. C. Huang**, *et al*. 2004. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc. Natl. Acad. Sci. USA **101:**10012-10017.

153. **Ratia, K., S. Pegan, J. Takayama, K. Sleeman, M. Coughlin, S. Baliji, R. Chaudhuri, W. Fu**, *et al*. 2008. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc. Natl. Acad. Sci. USA **105:**16119-16124.

154. **Crotty, S., D. Maag, J. J. Arnold, W. Zhong, J. Y. Lau, Z. Hong, R. Andino, and C. E. Cameron.** 2000. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. **6:**1375-1379.

155. **Morgenstern, B., M. Michaelis, P. C. Baer, H. W. Doerr, and J. Cinatl, Jr.** 2005. Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem. Biophys. Res. Commun. **326:**905-908.

156. **Stroher, U., A. DiCaro, Y. Li, J. E. Strong, F. Aoki, F. Plummer, S. M. Jones, and H. Feldmann.** 2004. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon- alpha. J. Infect. Dis. **189:**1164-1167.

157. **Saijo, M., S. Morikawa, S. Fukushi, T. Mizutani, H. Hasegawa, N. Nagata, N. Iwata, and I. Kurane.** 2005. Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus. Antiviral Res. **66:**159-163.

158. **Knowles, S. R., E. J. Phillips, L. Dresser, and L. Matukas.** 2003. Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada. Clin. Infect. Dis. **37:**1139-1142.

159. **te Velthuis, A. J., S. H. van den Worm, A. C. Sims, R. S. Baric, E. J. Snijder, and M. J. van Hemert.** 2010. Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity *in vitro* and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog. **6:**e1001176.

160. **Liu, K., X. Feng, Z. Ma, C. Luo, B. Zhou, R. Cao, L. Huang, D. Miao**, *et al*. 2012. Antiviral activity of phage display selected peptides against Porcine reproductive and respiratory syndrome virus *in vitro*. Virology **432:**73-80.

161. **Tanner, J. A., B. J. Zheng, J. Zhou, R. M. Watt, J. Q. Jiang, K. L. Wong, Y. P. Lin, L. Y. Lu**, *et al*. 2005. The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus. Chem. Biol. **12:**303-311.

162. **Yang, N., J. A. Tanner, Z. Wang, J. D. Huang, B. J. Zheng, N. Zhu, and H. Sun.** 2007. Inhibition of SARS coronavirus helicase by bismuth complexes. Chem. Commun. (Camb)**:**4413-4415.

163. **Yang, N., J. A. Tanner, B. J. Zheng, R. M. Watt, M. L. He, L. Y. Lu, J. Q. Jiang, K. T. Shum**, *et al*. 2007. Bismuth complexes inhibit the SARS coronavirus. Angew. Chem. Int. Ed. Engl. **46:**6464-6468.

164. **Yu, M. S., J. Lee, J. M. Lee, Y. Kim, Y. W. Chin, J. G. Jee, Y. S. Keum, and Y. J. Jeong.** 2012. Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13. Bioorg. Med. Chem. Lett. **22:**4049-4054.

165. **Kim, M. K., M. S. Yu, H. R. Park, K. B. Kim, C. Lee, S. Y. Cho, J. Kang, H. Yoon**, *et al*. 2011. 2,6-Bis-arylmethyloxy-5-hydroxychromones with antiviral activity against both hepatitis C virus (HCV) and SARS-associated coronavirus (SCV). Eur. J. Med. Chem. **46:**5698-5704.

166. **Bouvet, M., C. Debarnot, I. Imbert, B. Selisko, E. J. Snijder, B. Canard, and E. Decroly.** 2010. In vitro reconstitution of SARS-coronavirus mRNA cap methylation. PLoS Pathog. **6:**e1000863.

167. **He, R., A. Adonov, M. Traykova-Adonova, J. Cao, T. Cutts, E. Grudesky, Y. Deschambaul, J. Berry**, *et al*. 2004. Potent and selective inhibition of SARS coronavirus replication by aurintricarboxylic acid. Biochem. Biophys. Res. Commun. **320:**1199-1203.

168. **Ke, M., Y. Chen, A. Wu, Y. Sun, C. Su, H. Wu, X. Jin, J. Tao**, *et al*. 2012. Short peptides derived from the interaction domain of SARS coronavirus nonstructural protein nsp10 can suppress the 2′-O-methyltransferase activity of nsp10/nsp16 complex. Virus Res. **167:**322-328.

169. **Wilson, L., P. Gage, and G. Ewart.** 2006. Hexamethylene amiloride blocks E protein ion channels and inhibits coronavirus replication. Virology **353:**294-306.

170. **Neuman, B. W., D. A. Stein, A. D. Kroeker, M. J. Churchill, A. M. Kim, P. Kuhn, P. Dawson, H. M. Moulton**, *et al*. 2005. Inhibition, escape, and attenuated growth of severe acute respiratory syndrome coronavirus treated with antisense morpholino oligomers. J. Virol. **79:**9665-9676.

171. **Burrer, R., B. W. Neuman, J. P. Ting, D. A. Stein, H. M. Moulton, P. L. Iversen, P. Kuhn, and M. J. Buchmeier.** 2007. Antiviral effects of antisense morpholino oligomers in murine coronavirus infection models. J. Virol. **81:**5637-5648.

172. **Ahn, D. G., W. Lee, J. K. Choi, S. J. Kim, E. P. Plant, F. Almazan, D. R. Taylor, L. Enjuanes, and J. W. Oh.** 2011. Interference of ribosomal frameshifting by antisense peptide nucleic acids suppresses SARS coronavirus replication. Antiviral Res. **91:**1-10.

173. **van den Born, E., D. A. Stein, P. L. Iversen, and E. J. Snijder.** 2005. Antiviral activity of morpholino oligomers designed to block various aspects of Equine arteritis virus amplification in cell culture. J. Gen. Virol. **86:**3081-3090.

174. **Zhang, Y. J., D. A. Stein, S. M. Fan, K. Y. Wang, A. D. Kroeker, X. J. Meng, P. L. Iversen, and D. O. Matson.** 2006. Suppression of porcine reproductive and respiratory syndrome virus replication by morpholino antisense oligomers. Vet. Microbiol. **117:**117-129.

175. **Patel, D., T. Opriessnig, D. A. Stein, P. G. Halbur, X. J. Meng, P. L. Iversen, and Y. J. Zhang.** 2008. Peptide-conjugated morpholino oligomers inhibit porcine reproductive and respiratory syndrome virus replication. Antiviral Res. **77:**95-107.

176. **Han, X., S. Fan, D. Patel, and Y. J. Zhang.** 2009. Enhanced inhibition of porcine reproductive and respiratory syndrome virus replication by combination of morpholino oligomers. Antiviral Res. **82:**59-66.

177. **Opriessnig, T., D. Patel, R. Wang, P. G. Halbur, X. J. Meng, D. A. Stein, and Y. J. Zhang.** 2011. Inhibition of porcine reproductive and respiratory syndrome virus infection in piglets by a peptide-conjugated morpholino oligomer. Antiviral Res. **91:**36-42.

178. **He, Y. X., R. H. Hua, Y. J. Zhou, H. J. Qiu, and G. Z. Tong.** 2007. Interference of porcine reproductive and respiratory syndrome virus replication on MARC-145 cells using DNA-based short interfering RNAs. Antiviral Res. **74:**83-91.

179. **Li, G., P. Jiang, Y. Li, X. Wang, J. Huang, J. Bai, J. Cao, B. Wu**, *et al*. 2009. Inhibition of porcine reproductive and respiratory syndrome virus replication by adenovirus-mediated RNA interference both in porcine alveolar macrophages and swine. Antiviral Res. **82:**157-165.

180. **Heinrich, A., D. Riethmuller, M. Gloger, G. F. Schusser, M. Giese, and S. Ulbert.** 2009. RNA interference protects horse cells *in vitro* from infection with Equine Arteritis Virus. Antiviral Res. **81:**209-216.

181. **Zhang, Y., T. Li, L. Fu, C. Yu, Y. Li, X. Xu, Y. Wang, H. Ning**, *et al*. 2004. Silencing SARS-CoV Spike protein expression in cultured cells by RNA interference. FEBS Lett. **560:**141-146.

182. **Wu, C. J., H. W. Huang, C. Y. Liu, C. F. Hong, and Y. L. Chan.** 2005. Inhibition of SARS-CoV replication by siRNA. Antiviral Res. **65:**45-48.

183. **DeVincenzo, J. P.** 2012. The promise, pitfalls and progress of RNA-interference-based antiviral therapy for respiratory viruses. Antivir. Ther. **17:**213-225.

184. **Burnett, J. C., J. J. Rossi, and K. Tiemann.** 2011. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol. J. **6:**1130-1146.

185. **Shi, Y., D. H. Yang, J. Xiong, J. Jia, B. Huang, and Y. X. Jin.** 2005. Inhibition of genes expression of SARS coronavirus by synthetic small interfering RNAs. Cell Res. **15:**193-200.

186. **Li, B. J., Q. Tang, D. Cheng, C. Qin, F. Y. Xie, Q. Wei, J. Xu, Y. Liu**, *et al*. 2005. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat. Med. **11:**944-951.

187. **Stockman, L. J., R. Bellamy, and P. Garner.** 2006. SARS: systematic review of treatment effects. PLoS Med. **3:**e343.

188. **Garlinghouse, L. E., Jr., A. L. Smith, and T. Holford.** 1984. The biological relationship of mouse hepatitis virus (MHV) strains and interferon: *in vitro* induction and sensitivities. Arch. Virol. **82:**19-29.

189. **Taguchi, F., and S. G. Siddell.** 1985. Difference in sensitivity to interferon among mouse hepatitis viruses with high and low virulence for mice. Virology **147:**41-48.

190. **Haagmans, B. L., T. Kuiken, B. E. Martina, R. A. Fouchier, G. F. Rimmelzwaan, G. van Amerongen, D. van Riel, T. de Jong**, *et al*. 2004. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat. Med. **10:**290-293.

191. **Paragas, J., L. M. Blatt, C. Hartmann, J. W. Huggins, and T. P. Endy.** 2005. Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models. Antiviral Res. **66:**99-102.

192. **Zheng, B., M. L. He, K. L. Wong, C. T. Lum, L. L. Poon, Y. Peng, Y. Guan, M. C. Lin, and H. F. Kung.** 2004. Potent inhibition of SARS-associated coronavirus (SCOV) infection and replication by type I interferons (IFN-alpha/beta) but not by type II interferon (IFN-gamma). J. Interferon Cytokine Res. **24:**388-390.

193. **Dusheiko, G.** 1997. Side effects of alpha interferon in chronic hepatitis C. Hepatology **26:**112S-121S.

194. **Mitsuki, Y. Y., K. Ohnishi, H. Takagi, M. Oshima, T. Yamamoto, F. Mizukoshi, K. Terahara, K. Kobayashi**, *et al*. 2008. A single amino acid substitution in the S1 and S2 Spike protein domains determines the neutralization escape phenotype of SARS-CoV. Microbes Infect. **10:**908-915.

195. **Salonen, A., T. Ahola, and L. Kaariainen.** 2005. Viral RNA replication in association with cellular membranes. Curr. Top. Microbiol. Immunol. **285:**139-173.

196. **Sawicki, S. G., D. L. Sawicki, and S. G. Siddell.** 2007. A contemporary view of coronavirus transcription. J. Virol. **81:**20-29.

197. **Ng, L. F., and D. X. Liu.** 2002. Membrane association and dimerization of a cysteine-rich, 16-kilodalton polypeptide released from the C-terminal region of the coronavirus infectious bronchitis virus 1a polyprotein. J. Virol. **76:**6257-6267.

198. **Harcourt, B. H., D. Jukneliene, A. Kanjanahaluethai, J. Bechill, K. M. Severson, C. M. Smith, P. A. Rota, and S. C. Baker.** 2004. Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity. J. Virol. **78:**13600-13612.

199. **Shi, S. T., J. J. Schiller, A. Kanjanahaluethai, S. C. Baker, J. W. Oh, and M. M. Lai.** 1999. Colocalization and membrane association of murine hepatitis virus gene 1 products and De novo-synthesized viral RNA in infected cells. J. Virol. **73:**5957-5969.

200. **Denison, M. R., W. J. Spaan, Y. van der Meer, C. A. Gibson, A. C. Sims, E. Prentice, and X. T. Lu.** 1999. The putative helicase of the coronavirus mouse hepatitis virus is processed from the replicase gene polyprotein and localizes in complexes that are active in viral RNA synthesis. J. Virol. **73:**6862-6871.

201. **Pedersen, K. W., M. Y. van der, N. Roos, and E. J. Snijder.** 1999. Open reading frame 1a-encoded subunits of the arterivirus replicase induce endoplasmic reticulum-derived double-membrane vesicles which carry the viral replication complex. J. Virol. **73:**2016-2026.

202. **van Dinten, L. C., A. L. Wassenaar, A. E. Gorbalenya, W. J. Spaan, and E. J. Snijder.** 1996. Processing of the equine arteritis virus replicase ORF1b protein: identification of cleavage products containing the putative viral polymerase and helicase domains. J. Virol. **70:**6625-6633.

203. **Bi, W., J. D. Pinon, S. Hughes, P. J. Bonilla, K. V. Holmes, S. R. Weiss, and J. L. Leibowitz.** 1998. Localization of mouse hepatitis virus open reading frame 1A derived proteins. J. Neurovirol. **4:**594-605.

204. **Bost, A. G., R. H. Carnahan, X. T. Lu, and M. R. Denison.** 2000. Four proteins processed from the replicase gene polyprotein of mouse hepatitis virus colocalize in the cell periphery and adjacent to sites of virion assembly. J. Virol. **74:**3379-3387.

205. **Bost, A. G., E. Prentice, and M. R. Denison.** 2001. Mouse hepatitis virus replicase protein complexes are translocated to sites of M protein accumulation in the ERGIC at late times of infection. Virology **285:**21-29.

206. **Ivanov, K. A., V. Thiel, J. C. Dobbe, Y. van der Meer, E. J. Snijder, and J. Ziebuhr.** 2004. Multiple enzymatic activities associated with severe acute respiratory syndrome coronavirus helicase. J. Virol. **78:**5619-5632.

207. **Prentice, E., J. McAuliffe, X. Lu, K. Subbarao, and M. R. Denison.** 2004. Identification and characterization of severe acute respiratory syndrome coronavirus replicase proteins. J. Virol. **78:**9977-9986.

208. **Snijder, E. J., M. Y. van der, J. Zevenhoven-Dobbe, J. J. Onderwater, M. J. van der, H. K. Koerten, and A. M. Mommaas.** 2006. Ultrastructure and origin of membrane vesicles associated with the severe acute respiratory syndrome coronavirus replication complex. J. Virol. **80:**5927-5940.

209. **Pol, J. M., F. Wagenaar, and J. E. Reus.** 1997. Comparative morphogenesis of three PRRS virus strains. Vet. Microbiol. **55:**203-208.

210. **Wood, O., N. Tauraso, and H. Liebhaber.** 1970. Electron microscopic study of tissue cultures infected with simian haemorrhagic fever virus. J. Gen. Virol. **7:**129-136.

211. **Goldsmith, C. S., K. M. Tatti, T. G. Ksiazek, P. E. Rollin, J. A. Comer, W. W. Lee, P. A. Rota, B. Bankamp**, *et al*. 2004. Ultrastructural characterization of SARS coronavirus. Emerg. Infect. Dis. **10:**320-326.

212. **Ng, M. L., S. H. Tan, E. E. See, E. E. Ooi, and A. E. Ling.** 2003. Proliferative growth of SARS coronavirus in Vero E6 cells. J. Gen. Virol. **84:**3291-3303.

213. **Snijder, E. J., and J. J. Meulenberg.** 1998. The molecular biology of arteriviruses. J. Gen. Virol. **79 (Pt 5):**961-979.

214. **Van Aken, D., J. Zevenhoven-Dobbe, A. E. Gorbalenya, and E. J. Snijder.** 2006. Proteolytic maturation of replicase polyprotein pp1a by the nsp4 main proteinase is essential for equine arteritis virus replication and includes internal cleavage of nsp7. J. Gen. Virol. **87:**3473-3482.

215. **Beerens, N., B. Selisko, S. Ricagno, I. Imbert, L. van der Zanden, E. J. Snijder, and B. Canard.** 2007. De novo initiation of RNA synthesis by the arterivirus RNA-dependent RNA polymerase. J. Virol.

216. **Seybert, A., L. C. van Dinten, E. J. Snijder, and J. Ziebuhr.** 2000. Biochemical characterization of the equine arteritis virus helicase suggests a close functional relationship between arterivirus and coronavirus helicases. J. Virol. **74:**9586-9593.

217. **Snijder, E. J., H. van Tol, N. Roos, and K. W. Pedersen.** 2001. Non-structural proteins 2 and 3 interact to modify host cell membranes during the formation of the arterivirus replication complex. J. Gen. Virol. **82:**985-994.

218. **Franklin, R. M.** 1967. Replication of bacteriophage ribonucleic acid: some physical properties of single-stranded, double-stranded, and branched viral ribonucleic acid. J. Virol. **1:**64-75.

219. **Sawicki, S. G., and D. L. Sawicki.** 1990. Coronavirus transcription: subgenomic mouse hepatitis virus replicative intermediates function in RNA synthesis. J. Virol. **64:**1050-1056.

220. **de Vries, A. A., E. D. Chirnside, M. C. Horzinek, and P. J. Rottier.** 1992. Structural proteins of equine arteritis virus. J. Virol. **66:**6294-6303.

221. **Igarashi, A.** 1978. Isolation of a Singh's Aedes albopictus cell clone sensitive to Dengue and Chikungunya viruses. J. Gen. Virol. **40:**531-544.

222. **Snijder, E. J., A. L. Wassenaar, and W. J. Spaan.** 1994. Proteolytic processing of the replicase ORF1a protein of equine arteritis virus. J. Virol. **68:**5755-5764.

223. **van Dinten, L. C., S. Rensen, A. E. Gorbalenya, and E. J. Snijder.** 1999. Proteolytic processing of the open reading frame 1b-encoded part of arterivirus replicase is mediated by nsp4 serine protease and Is essential for virus replication. J. Virol. **73:**2027-2037.

224. **van Marle, G., L. C. van Dinten, W. J. Spaan, W. Luytjes, and E. J. Snijder.** 1999. Characterization of an equine arteritis virus replicase mutant defective in subgenomic mRNA synthesis. J. Virol. **73:**5274-5281.

225. **van Marle, G., J. C. Dobbe, A. P. Gultyaev, W. Luytjes, W. J. Spaan, and E. J. Snijder.** 1999. Arterivirus discontinuous mRNA transcription is guided by base pairing between sense and antisense transcription-regulating sequences. Proc. Natl. Acad. Sci. USA **96:**12056-12061.

226. **Chu, P. W., and E. G. Westaway.** 1985. Replication strategy of Kunjin virus: evidence for recycling role of replicative form RNA as template in semiconservative and asymmetric replication. Virology **140:**68-79.

227. **Grun, J. B., and M. A. Brinton.** 1986. Characterization of West Nile virus RNA-dependent RNA polymerase and cellular terminal adenylyl and uridylyl transferases in cell-free extracts. J. Virol. **60:**1113-1124.

228. **Barton, D. J., S. G. Sawicki, and D. L. Sawicki.** 1991. Solubilization and immunoprecipitation of alphavirus replication complexes. J. Virol. **65:**1496-1506.

229. **Uchil, P. D., and V. Satchidanandam.** 2003. Characterization of RNA synthesis, replication mechanism, and *in vitro* RNA-dependent RNA polymerase activity of Japanese encephalitis virus. Virology **307:**358-371.

230. **Hardy, S. F., T. L. German, L. S. Loesch-Fries, and T. C. Hall.** 1979. Highly active template-specific RNA-dependent RNA polymerase from barley leaves infected with brome mosaic virus. Proc. Natl. Acad. Sci. USA **76:**4956-4960.

231. **Snijder, E. J., A. L. Wassenaar, L. C. van Dinten, W. J. Spaan, and A. E. Gorbalenya.** 1996. The arterivirus nsp4 protease is the prototype of a novel group of chymotrypsin-like enzymes, the 3C-like serine proteases. J. Biol. Chem. **271:**4864-4871.

232. **Wassenaar, A. L., W. J. Spaan, A. E. Gorbalenya, and E. J. Snijder.** 1997. Alternative proteolytic processing of the arterivirus replicase ORF1a polyprotein: evidence that NSP2 acts as a cofactor for the NSP4 serine protease. J. Virol. **71:**9313-9322.

233. **Snijder, E. J., A. L. Wassenaar, and W. J. Spaan.** 1992. The 5′ end of the equine arteritis virus replicase gene encodes a papainlike cysteine protease. J. Virol. **66:**7040-7048.

234. **Tijms, M. A., D. D. Nedialkova, J. C. Zevenhoven-Dobbe, A. E. Gorbalenya, and E. J. Snijder.** 2007. Arterivirus subgenomic mRNA synthesis and virion biogenesis depend on the multifunctional nsp1 autoprotease. J. Virol.

235. **Tijms, M. A., L. C. van Dinten, A. E. Gorbalenya, and E. J. Snijder.** 2001. A zinc finger-containing papain-like protease couples subgenomic mRNA synthesis to genome translation in a positive-stranded RNA virus. Proc. Natl. Acad. Sci. USA **98:**1889-1894.

236. **Brayton, P. R., M. M. Lai, C. D. Patton, and S. A. Stohlman.** 1982. Characterization of two RNA polymerase activities induced by mouse hepatitis virus. J. Virol. **42:**847-853.

237. **Brayton, P. R., S. A. Stohlman, and M. M. Lai.** 1984. Further characterization of mouse hepatitis virus RNA-dependent RNA polymerases. Virology **133:**197-201.

238. **Mahy, B. W., S. Siddell, H. Wege, and V. ter Meulen.** 1983. RNA-dependent RNA polymerase activity in murine coronavirus-infected cells. J. Gen. Virol. **64 (Pt 1):**103-111.

239. **Compton, S. R., D. B. Rogers, K. V. Holmes, D. Fertsch, J. Remenick, and J. J. McGowan.** 1987. In vitro replication of mouse hepatitis virus strain A59. J. Virol. **61:**1814-1820.

240. **Dennis, D. E., and D. A. Brian.** 1982. RNA-dependent RNA polymerase activity in coronavirus-infected cells. J. Virol. **42:**153-164.

241. **Sawicki, S. G., and D. L. Sawicki.** 1986. Coronavirus minus-strand RNA synthesis and effect of cycloheximide on coronavirus RNA synthesis. J. Virol. **57:**328-334.

242. **Barton, D. J., and J. B. Flanegan.** 1993. Coupled translation and replication of poliovirus RNA *in vitro*: synthesis of functional 3D polymerase and infectious virus. J. Virol. **67:**822-831.

243. **Ehrenfeld, E., and D. Brown.** 1981. Stability of poliovirus RNA in cell-free translation systems utilizing two initiation sites. J. Biol. Chem. **256:**2656-2661.

244. **Chu, P. W., and E. G. Westaway.** 1987. Characterization of Kunjin virus RNA-dependent RNA polymerase: reinitiation of synthesis *in vitro*. Virology **157:**330-337.

245. **Tomassini, J. E., E. Boots, L. Gan, P. Graham, V. Munshi, B. Wolanski, J. F. Fay, K. Getty, and R. LaFemina.** 2003. An *in vitro* Flaviviridae replicase system capable of authentic RNA replication. Virology **313:**274-285.

246. **Sreevalsan, T., and F. H. Yin.** 1969. Sindbis virus-induced viral ribonucleic acid polymerase. J. Virol. **3:**599-604.

247. **Polatnick, J., and R. B. Arlinghaus.** 1967. Foot-and-mouth disease virus-induced ribonucleic acid polymerase in baby hamster kidney cells. Virology **31:**601-608.

248. **Rosenberg, H., B. Diskin, L. Oron, and A. Traub.** 1972. Isolation and subunit structure of polycytidylate-dependent RNA polymerase of encephalomyocarditis virus. Proc. Natl. Acad. Sci. USA **69:**3815-3819.

249. **Quadt, R., and E. M. Jaspars.** 1990. Purification and characterization of brome mosaic virus RNA-dependent RNA polymerase. Virology **178:**189-194.

250. **Baltimore, D., and R. M. Franklin.** 1963. A New Ribonucleic Acid Polymerase Appearing after Mengovirus Infection of L-Cells. J. Biol. Chem. **238:**3395-3400.

251. **Svitkin, Y. V., and N. Sonenberg.** 2003. Cell-free synthesis of encephalomyocarditis virus. J. Virol. **77:**6551-6555.

252. **Yin, F. H., and E. Knight, Jr.** 1972. In vivo and *in vitro* synthesis of human rhinovirus type 2 ribonucleic acid. J. Virol. **10:**93-98.

253. **Warrilow, D., W. B. Lott, S. Greive, and E. J. Gowans.** 2000. Properties of the bovine viral diarrhoea virus replicase in extracts of infected MDBK cells. Arch. Virol. **145:**2163-2171.

254. **Lai, V. C., S. Dempsey, J. Y. Lau, Z. Hong, and W. Zhong.** 2003. In vitro RNA replication directed by replicase complexes isolated from the subgenomic replicon cells of hepatitis C virus. J. Virol. **77:**2295-2300.

255. **Hardy, R. W., J. Marcotrigiano, K. J. Blight, J. E. Majors, and C. M. Rice.** 2003. Hepatitis C virus RNA synthesis in a cell-free system isolated from replicon-containing hepatoma cells. J. Virol. **77:**2029-2037.

256. **Takegami, T., and S. Hotta.** 1989. In vitro synthesis of Japanese encephalitis virus (JEV) RNA: membrane and nuclear fractions of JEV-infected cells possess high levels of virus-specific RNA polymerase activity. Virus Res. **13:**337-350.

257. **Qureshi, A. A., and D. W. Trent.** 1972. Saint Louis encephalitis viral ribonucleic acid replication complex. J. Virol. **9:**565-573.

258. **Li, M. L., Y. H. Lin, and V. Stollar.** 2005. A cell-free system for the synthesis of Sindbis virus subgenomic RNA: importance of the concentration of the initiating NTP. Virology **341:**24-33.

259. **Baltimore, D., H. J. Eggers, R. M. Franklin, and I. Tamm.** 1963. Poliovirus-induced RNA polymerase and the effects of virus-specific inhibitors on its production. Proc. Natl. Acad. Sci. USA **49:**843-849.

260. **Ali, N., K. D. Tardif, and A. Siddiqui.** 2002. Cell-free replication of the hepatitis C virus subgenomic replicon. J. Virol. **76:**12001-12007.

261. **Sun, J. H., S. Adkins, G. Faurote, and C. C. Kao.** 1996. Initiation of (-)-strand RNA synthesis catalyzed by the BMV RNA-dependent RNA polymerase: synthesis of oligonucleotides. Virology **226:**1-12.

262. **Molenkamp, R., B. C. Rozier, S. Greve, W. J. Spaan, and E. J. Snijder.** 2000. Isolation and characterization of an arterivirus defective interfering RNA genome. J. Virol. **74:**3156-3165.

263. **Egger, D., N. Teterina, E. Ehrenfeld, and K. Bienz.** 2000. Formation of the poliovirus replication complex requires coupled viral translation, vesicle production, and viral RNA synthesis. J. Virol. **74:**6570-6580.

264. **Barton, D. J., E. P. Black, and J. B. Flanegan.** 1995. Complete replication of poliovirus *in vitro*: preinitiation RNA replication complexes require soluble cellular factors for the synthesis of VPg-linked RNA. J. Virol. **69:**5516-5527.

265. **Shi, S. T., K. J. Lee, H. Aizaki, S. B. Hwang, and M. M. Lai.** 2003. Hepatitis C virus RNA replication occurs on a detergent-resistant membrane that cofractionates with caveolin-2. J. Virol. **77:**4160-4168.

266. **Westaway, E. G., A. A. Khromykh, and J. M. Mackenzie.** 1999. Nascent flavivirus RNA colocalized in situ with double-stranded RNA in stable replication complexes. Virology **258:**108-117.

267. **Arlinghaus, R. B., and J. Polatnick.** 1969. In vitro products of a membrane-free foot-and-mouth disease virus ribonucleic acid polymerase. Virology **37:**252-261.

268. **Etchison, D., and E. Ehrenfeld.** 1981. Comparison of replication complexes synthesizing poliovirus RNA. Virology **111:**33-46.

269. **Ehrenfeld, E., J. V. Maizel, and D. F. Summers.** 1970. Soluble RNA polymerase complex from poliovirus-infected HeLa cells. Virology **40:**840-846.

270. **Molenkamp, R., H. van Tol, B. C. Rozier, M. Y. van der, W. J. Spaan, and E. J. Snijder.** 2000. The arterivirus replicase is the only viral protein required for genome replication and subgenomic mRNA transcription. J. Gen. Virol. **81:**2491-2496.

271. **Bose, S., M. Mathur, P. Bates, N. Joshi, and A. K. Banerjee.** 2003. Requirement for cyclophilin A for the replication of vesicular stomatitis virus New Jersey serotype. J. Gen. Virol. **84:**1687-1699.

272. **Briggs, C. J., D. E. Ott, L. V. Coren, S. Oroszlan, and J. Tozser.** 1999. Comparison of the effect of FK506 and cyclosporin A on virus production in H9 cells chronically and newly infected by HIV-1. Arch. Virol. **144:**2151-2160.

273. **Kambara, H., H. Tani, Y. Mori, T. Abe, H. Katoh, T. Fukuhara, S. Taguwa, K. Moriishi, and Y. Matsuura.** 2011. Involvement of cyclophilin B in the replication of Japanese encephalitis virus. Virology **412:**211-219.

274. **Nakagawa, M., N. Sakamoto, N. Enomoto, Y. Tanabe, N. Kanazawa, T. Koyama, M. Kurosaki, S. Maekawa**, *et al*. 2004. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem. Biophys. Res. Commun. **313:**42-47.

275. **Qing, M., F. Yang, B. Zhang, G. Zou, J. M. Robida, Z. Yuan, H. Tang, and P. Y. Shi.** 2009. Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein. Antimicrob. Agents Chemother. **53:**3226-3235.

276. **de Wilde, A. H., J. C. Zevenhoven-Dobbe, Y. van der Meer, V. Thiel, K. Narayanan, S. Makino, E. J. Snijder, and M. J. van Hemert.** 2011. Cyclosporin A inhibits the replication of diverse coronaviruses. J. Gen. Virol. **92:**2542-2548.

277. **Pfefferle, S., J. Schopf, M. Kogl, C. C. Friedel, M. A. Muller, J. Carbajo-Lozoya, T. Stellberger, E. von Dall'armi**, *et al*. 2011. The SARS-Coronavirus-Host Interactome: Identification of Cyclophilins as Target for Pan-Coronavirus Inhibitors. PLoS Pathog. **7:**e1002331.

278. **Tanaka, Y., Y. Sato, S. Osawa, M. Inoue, S. Tanaka, and T. Sasaki.** 2012. Suppression of feline coronavirus replication *in vitro* by cyclosporin A. Vet. Res. **43:**41.

279. **Davis, T. L., J. R. Walker, V. Campagna-Slater, P. J. Finerty, R. Paramanathan, G. Bernstein, F. MacKenzie, W. Tempel**, *et al*. 2010. Structural and biochemical characterization of the human cyclophilin family of peptidyl-prolyl isomerases. PLoS Biol. **8:**e1000439.

280. **Barik, S.** 2006. Immunophilins: for the love of proteins. Cell. Mol. Life Sci. **63:**2889-2900.

281. **Nagy, P. D., R. Y. Wang, J. Pogany, A. Hafren, and K. Makinen.** 2011. Emerging picture of host chaperone and cyclophilin roles in RNA virus replication. Virology **411:**374-382.

282. **Tedesco, D., and L. Haragsim.** 2012. Cyclosporine: a review. J. Transplant. **2012:**230386.

283. **Flisiak, R., S. V. Feinman, M. Jablkowski, A. Horban, W. Kryczka, M. Pawlowska, J. E. Heathcote, G. Mazzella**, *et al*. 2009. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology **49:**1460-1468.

284. **Flisiak, R., A. Horban, P. Gallay, M. Bobardt, S. Selvarajah, A. Wiercinska-Drapalo, E. Siwak, I. Cielniak**, *et al*. 2008. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology **47:**817-826.

285. **Lawitz, E., E. Godofsky, R. Rouzier, T. Marbury, T. Nguyen, J. Ke, M. Huang, J. Praestgaard**, *et al*. 2011. Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy. Antiviral Res. **89:**238-245.

286. **de Groot, R. J., J. A. Cowley, L. Enjuanes, K. S. Faaberg, S. Perlman, P. J. Rottier, E. J. Snijder, J. Ziebuhr, and A. E. Gorbalenya.** 2012. Order of Nidovirales, p. 785-795. In A. King, M. Adams, E. Carstens, and E. J. Lefkowitz (ed.), Virus Taxonomy, the 9th Report of the International Committee on Taxonomy of Viruses. Academic Press.

287. **Snijder, E. J., and W. J. M. Spaan.** 2007. Arteriviruses, p. 1337-1355. In D. M. Knipe and P. M. Howley (ed.), Fields Virology, 5 ed. Lippincott, Williams & Wilkins, Philadelphia, Pa.

288. **Nedialkova, D. D., A. E. Gorbalenya, and E. J. Snijder.** 2010. Arterivirus Nsp1 modulates the accumulation of minus-strand templates to control the relative abundance of viral mRNAs. PLoS Pathog. **6:**e1000772.

289. **Kim, H. S., J. Kwang, I. J. Yoon, H. S. Joo, and M. L. Frey.** 1993. Enhanced replication of porcine reproductive and respiratory syndrome (PRRS) virus in a homogeneous subpopulation of MA-104 cell line. Arch. Virol. **133:**477-483.

290. **Bryans, J. T., M. E. Crowe, E. R. Doll, and W. H. McCollum.** 1957. Isolation of a filterable agent causing arteritis of horses and abortion by mares; its differentiation from the equine abortion (influenza) virus. Cornell Vet. **47:**3-41.

291. **van den Born, E., C. C. Posthuma, K. Knoops, and E. J. Snijder.** 2007. An infectious recombinant equine arteritis virus expressing green fluorescent protein from its replicase gene. J. Gen. Virol. **88:**1196-1205.

292. **Fang, Y., R. R. Rowland, M. Roof, J. K. Lunney, J. Christopher-Hennings, and E. A. Nelson.** 2006. A full-length cDNA infectious clone of North American type 1 porcine reproductive and respiratory syndrome virus: expression of green fluorescent protein in the Nsp2 region. J. Virol. **80:**11447-11455.

293. **Sun, Z., Y. Li, R. Ransburgh, E. J. Snijder, and Y. Fang.** 2012. Nonstructural protein 2 of porcine reproductive and respiratory syndrome virus inhibits the antiviral function of interferon-stimulated gene 15. J. Virol. **86:**3839-3850.

294. **MacLachlan, N. J., U. B. Balasuriya, J. F. Hedges, T. M. Schweidler, W. H. McCollum, P. J. Timoney, P. J. Hullinger, and J. F. Patton.** 1998. Serologic response of horses to the structural proteins of equine arteritis virus. J. Vet. Diagn. Invest. **10:**229-236.

295. **Knoops, K., C. Swett-Tapia, S. H. van den Worm, A. J. Te Velthuis, A. J. Koster, A. M. Mommaas, E. J. Snijder, and M. Kikkert.** 2010. Integrity of the early secretory pathway promotes, but is not required for, severe acute respiratory syndrome coronavirus RNA synthesis and virus-induced remodeling of endoplasmic reticulum membranes. J. Virol. **84:**833-846.

296. **Schreiber, S. L., and G. R. Crabtree.** 1992. The mechanism of action of cyclosporin A and FK506. Immunol. Today **13:**136-142.

297. **Hopkins, S., B. Dimassimo, P. Rusnak, D. Heuman, J. Lalezari, A. Sluder, B. Scorneaux, S. Mosier**, *et al*. 2012. The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection. J. Hepatol. **57:**47-54.

298. **Wenger, R., M. Mutter, P. Garrouste, R. Lysek, O. Turpin, G. Vuagniaux, V. Nicolas, L. Novaroli Zanolari, and R. Crabbé.** November 2009. Cycloundecadepsipeptide compounds and use of said compounds as a medicament. patent WO 2010/052559.

299. **Watashi, K., M. Hijikata, M. Hosaka, M. Yamaji, and K. Shimotohno.** 2003. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology **38:**1282-1288.

300. **Damaso, C. R., and S. J. Keller.** 1994. Cyclosporin A inhibits vaccinia virus replication *in vitro*. Arch. Virol. **134:**303-319.

301. **Chatterji, U., P. Lim, M. D. Bobardt, S. Wieland, D. G. Cordek, G. Vuagniaux, F. Chisari, C. E. Cameron**, *et al*. 2010. HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors. J. Hepatol. **53:**50-56.

302. **Fernandes, F., I. U. Ansari, and R. Striker.** 2010. Cyclosporine inhibits a direct interaction between cyclophilins and hepatitis C NS5A. PLoS One **5:**e9815.

303. **Gaither, L. A., J. Borawski, L. J. Anderson, K. A. Balabanis, P. Devay, G. Joberty, C. Rau, M. Schirle**, *et al*. 2010. Multiple cyclophilins involved in different cellular pathways mediate HCV replication. Virology **397:**43-55.

304. **Coelmont, L., X. Hanoulle, U. Chatterji, C. Berger, J. Snoeck, M. Bobardt, P. Lim, I. Vliegen**, *et al*. 2010. DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One **5:**e13687.

305. **Foster, T. L., P. Gallay, N. J. Stonehouse, and M. Harris.** 2011. Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner. J. Virol. **85:**7460-7464.

306. **Chatterji, U., M. Bobardt, S. Selvarajah, F. Yang, H. Tang, N. Sakamoto, G. Vuagniaux, T. Parkinson, and P. Gallay.** 2009. The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J. Biol. Chem. **284:**16998-17005.

307. **Liu, Z., F. Yang, J. M. Robotham, and H. Tang.** 2009. Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex. J. Virol. **83:**6554-6565.

308. **Kaul, A., S. Stauffer, C. Berger, T. Pertel, J. Schmitt, S. Kallis, M. Zayas, V. Lohmann**, *et al*. 2009. Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog. **5:**e1000546.

309. **Watashi, K., N. Ishii, M. Hijikata, D. Inoue, T. Murata, Y. Miyanari, and K. Shimotohno.** 2005. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol. Cell **19:**111-122.

310. **Castro, A. P., T. M. Carvalho, N. Moussatche, and C. R. Damaso.** 2003. Redistribution of cyclophilin A to viral factories during vaccinia virus infection and its incorporation into mature particles. J. Virol. **77:**9052-9068.

311. **Liu, X., L. Sun, M. Yu, Z. Wang, C. Xu, Q. Xue, K. Zhang, X. Ye**, *et al*. 2009. Cyclophilin A interacts with influenza A virus M1 protein and impairs the early stage of the viral replication. Cell. Microbiol.

312. **Luo, C., H. Luo, S. Zheng, C. Gui, L. Yue, C. Yu, T. Sun, P. He**, *et al*. 2004. Nucleocapsid protein of SARS coronavirus tightly binds to human cyclophilin A. Biochem. Biophys. Res. Commun. **321:**557-565.

313. **Almazan, F., C. Galan, and L. Enjuanes.** 2004. The nucleoprotein is required for efficient coronavirus genome replication. J. Virol. **78:**12683-12688.

314. **Schelle, B., N. Karl, B. Ludewig, S. G. Siddell, and V. Thiel.** 2006. Nucleocapsid protein expression facilitates coronavirus replication. Adv. Exp. Med. Biol. **581:**43-48.

315. **Pang, X., M. Zhang, L. Zhou, F. Xie, H. Lu, W. He, S. Jiang, L. Yu, and X. Zhang.** 2011. Discovery of a potent peptidic cyclophilin A inhibitor Trp-Gly-Pro. Eur. J. Med. Chem. **46:**1701-1705.

316. **Puyang, X., D. L. Poulin, J. E. Mathy, L. J. Anderson, S. Ma, Z. Fang, S. Zhu, K. Lin**, *et al*. 2010. Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors. Antimicrob. Agents Chemother. **54:**1981-1987.

317. **Perlman, S., and J. Netland.** 2009. Coronaviruses post-SARS: update on replication and pathogenesis. Nat. Rev. Microbiol. **7:**439-450.

318. **Tong, T. R.** 2009. Drug targets in severe acute respiratory syndrome (SARS) virus and other coronavirus infections. Infect. Disord. Drug Targets **9:**223-245.

319. **Vincent, M. J., E. Bergeron, S. Benjannet, B. R. Erickson, P. E. Rollin, T. G. Ksiazek, N. G. Seidah, and S. T. Nichol.** 2005. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J. **2:**69.

320. **de Haan, C. A., and P. J. Rottier.** 2006. Hosting the severe acute respiratory syndrome coronavirus: specific cell factors required for infection. Cell. Microbiol. **8:**1211-1218.

321. **Vogels, M. W., B. W. van Balkom, D. V. Kaloyanova, J. J. Batenburg, A. J. Heck, J. B. Helms, P. J. Rottier, and C. A. de Haan.** 2011. Identification of host factors involved in coronavirus replication by quantitative proteomics analysis. Proteomics **11:**64-80.

322. **Zhang, L., Z. P. Zhang, X. E. Zhang, F. S. Lin, and F. Ge.** 2010. Quantitative proteomics analysis reveals BAG3 as a potential target to suppress severe acute respiratory syndrome coronavirus replication. J. Virol. **84:**6050-6059.

323. **Nakagawa, M., N. Sakamoto, Y. Tanabe, T. Koyama, Y. Itsui, Y. Takeda, C. H. Chen, S. Kakinuma**, *et al*. 2005. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology **129:**1031-1041.

324. **Sims, A. C., S. E. Burkett, B. Yount, and R. J. Pickles.** 2008. SARS-CoV replication and pathogenesis in an *in vitro* model of the human conducting airway epithelium. Virus Res. **133:**33-44.

325. **Cervantes-Barragan, L., R. Zust, R. Maier, S. Sierro, J. Janda, F. Levy, D. Speiser, P. Romero**, *et al*. 2010. Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity. MBio **1:**e00171-00110.

326. **Das Sarma, J., E. Scheen, S. H. Seo, M. Koval, and S. R. Weiss.** 2002. Enhanced green fluorescent protein expression may be used to monitor murine coronavirus spread *in vitro* and in the mouse central nervous system. J. Neurovirol. **8:**381-391.

327. **Ishii, N., K. Watashi, T. Hishiki, K. Goto, D. Inoue, M. Hijikata, T. Wakita, N. Kato, and K. Shimotohno.** 2006. Diverse effects of cyclosporine on hepatitis C virus strain replication. J. Virol. **80:**4510-4520.

328. **Manel, N., B. Hogstad, Y. Wang, D. E. Levy, D. Unutmaz, and D. R. Littman.** 2010. A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Nature **467:**214-217.

329. **te Velthuis, A. J., J. J. Arnold, C. E. Cameron, S. H. van den Worm, and E. J. Snijder.** 2010. The RNA polymerase activity of SARS-coronavirus nsp12 is primer dependent. Nucleic Acids Res. **38:**203-214.

330. **Paeshuyse, J., A. Kaul, E. De Clercq, B. Rosenwirth, J. M. Dumont, P. Scalfaro, R. Bartenschlager, and J. Neyts.** 2006. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication *in vitro*. Hepatology **43:**761-770.

331. **Ciesek, S., E. Steinmann, H. Wedemeyer, M. P. Manns, J. Neyts, N. Tautz, V. Madan, R. Bartenschlager**, *et al*. 2009. Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. Hepatology **50:**1638-1645.

332. **Chatterji, U., M. D. Bobardt, P. Lim, and P. A. Gallay.** 2010. Cyclophilin A-independent recruitment of NS5A and NS5B into hepatitis C virus replication complexes. J. Gen. Virol. **91:**1189-1193.

333. **Goto, K., K. Watashi, D. Inoue, M. Hijikata, and K. Shimotohno.** 2009. Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor. Cancer Sci. **100:**1943-1950.

334. **Krishnan, M. N., A. Ng, B. Sukumaran, F. D. Gilfoy, P. D. Uchil, H. Sultana, A. L. Brass, R. Adametz**, *et al*. 2008. RNA interference screen for human genes associated with West Nile virus infection. Nature **455:**242-245.

335. **Sessions, O. M., N. J. Barrows, J. A. Souza-Neto, T. J. Robinson, C. L. Hershey, M. A. Rodgers, J. L. Ramirez, G. Dimopoulos**, *et al*. 2009. Discovery of insect and human dengue virus host factors. Nature **458:**1047-1050.

336. **Zhou, H., M. Xu, Q. Huang, A. T. Gates, X. D. Zhang, J. C. Castle, E. Stec, M. Ferrer**, *et al*. 2008. Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe **4:**495-504.

337. **Ng, T. I., H. Mo, T. Pilot-Matias, Y. He, G. Koev, P. Krishnan, R. Mondal, R. Pithawalla**, *et al*. 2007. Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology. Hepatology **45:**1413-1421.

338. **Tai, A. W., Y. Benita, L. F. Peng, S. S. Kim, N. Sakamoto, R. J. Xavier, and R. T. Chung.** 2009. A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe **5:**298-307.

339. **Li, Q., A. L. Brass, A. Ng, Z. Hu, R. J. Xavier, T. J. Liang, and S. J. Elledge.** 2009. A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc. Natl. Acad. Sci. USA **106:**16410-16415.

340. **Reiss, S., I. Rebhan, P. Backes, I. Romero-Brey, H. Erfle, P. Matula, L. Kaderali, M. Poenisch**, *et al*. 2011. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe **9:**32-45.

341. **Supekova, L., F. Supek, J. Lee, S. Chen, N. Gray, J. P. Pezacki, A. Schlapbach, and P. G. Schultz.** 2008. Identification of human kinases involved in hepatitis C virus replication by small interference RNA library screening. J. Biol. Chem. **283:**29-36.

342. **Randall, G., M. Panis, J. D. Cooper, T. L. Tellinghuisen, K. E. Sukhodolets, S. Pfeffer, M. Landthaler, P. Landgraf**, *et al*. 2007. Cellular cofactors affecting hepatitis C virus infection and replication. Proc. Natl. Acad. Sci. USA **104:**12884-12889.

343. **Hao, L., A. Sakurai, T. Watanabe, E. Sorensen, C. A. Nidom, M. A. Newton, P. Ahlquist, and Y. Kawaoka.** 2008. Drosophila RNAi screen identifies host genes important for influenza virus replication. Nature **454:**890-893.

344. **Karlas, A., N. Machuy, Y. Shin, K. P. Pleissner, A. Artarini, D. Heuer, D. Becker, H. Khalil**, *et al*. 2010. Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. Nature **463:**818-822.

345. **Pyrc, K., B. Berkhout, and L. van der Hoek.** 2007. The novel human coronaviruses NL63 and HKU1. J. Virol. **81:**3051-3057.

346. **Narayanan, K., C. Huang, and S. Makino.** 2008. SARS coronavirus accessory proteins. Virus Res. **133:**113-121.

347. **Ratia, K., K. S. Saikatendu, B. D. Santarsiero, N. Barretto, S. C. Baker, R. C. Stevens, and A. D. Mesecar.** 2006. Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme. Proc. Natl. Acad. Sci. USA **103:**5717-5722.

348. **Zust, R., L. Cervantes-Barragan, M. Habjan, R. Maier, B. W. Neuman, J. Ziebuhr, K. J. Szretter, S. C. Baker**, *et al*. 2011. Ribose 2′-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat. Immunol. **12:**137-143.

349. **Ye, Y., K. Hauns, J. O. Langland, B. L. Jacobs, and B. G. Hogue.** 2007. Mouse hepatitis coronavirus A59 nucleocapsid protein is a type I interferon antagonist. J. Virol. **81:**2554-2563.

350. **Kopecky-Bromberg, S. A., L. Martinez-Sobrido, and P. Palese.** 2006. 7a protein of severe acute respiratory syndrome coronavirus inhibits cellular protein synthesis and activates p38 mitogen-activated protein kinase. J. Virol. **80:**785-793.

351. **Hussain, S., S. Perlman, and T. M. Gallagher.** 2008. Severe acute respiratory syndrome coronavirus protein 6 accelerates murine hepatitis virus infections by more than one mechanism. J. Virol. **82:**7212-7222.

352. **Coyne, C. B., R. Bozym, S. A. Morosky, S. L. Hanna, A. Mukherjee, M. Tudor, K. S. Kim, and S. Cherry.** 2011. Comparative RNAi screening reveals host factors involved in enterovirus infection of polarized endothelial monolayers. Cell Host Microbe **9:**70-82.

353. **Hsu, N. Y., O. Ilnytska, G. Belov, M. Santiana, Y. H. Chen, P. M. Takvorian, C. Pau, H. van der Schaar**, *et al*. 2010. Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell **141:**799-811.

354. **de Wilde, A. H., Y. Li, Y. van der Meer, G. Vuagniaux, R. Lysek, Y. Fang, E. J. Snijder, and M. J. van Hemert.** 2013. Cyclophilin inhibitors block arterivirus replication by interfering with viral RNA synthesis. J. Virol. **87:**1454-1464.

355. **van den Worm, S. H., K. K. Eriksson, J. C. Zevenhoven, F. Weber, R. Zust, T. Kuri, R. Dijkman, G. Chang**, *et al*. 2012. Reverse genetics of SARS-related coronavirus using vaccinia virus-based recombination. PLoS One **7:**e32857.

356. **Boutros, M., L. P. Bras, and W. Huber.** 2006. Analysis of cell-based RNAi screens. Genome Biol. **7:**R66.

357. **Beck, R., M. Rawet, F. T. Wieland, and D. Cassel.** 2009. The COPI system: molecular mechanisms and function. FEBS Lett. **583:**2701-2709.

358. **Niu, T. K., A. C. Pfeifer, J. Lippincott-Schwartz, and C. L. Jackson.** 2005. Dynamics of GBF1, a Brefeldin A-sensitive Arf1 exchange factor at the Golgi. Mol. Biol. Cell. **16:**1213-1222.

359. **Cherry, S., T. Doukas, S. Armknecht, S. Whelan, H. Wang, P. Sarnow, and N. Perrimon.** 2005. Genome-wide RNAi screen reveals a specific sensitivity of IRES-containing RNA viruses to host translation inhibition. Genes Dev. **19:**445-452.

360. **Chang, Y. J., C. Y. Liu, B. L. Chiang, Y. C. Chao, and C. C. Chen.** 2004. Induction of IL-8 release in lung cells via activator protein-1 by recombinant baculovirus displaying severe acute respiratory syndrome-coronavirus spike proteins: identification of two functional regions. J. Immunol. **173:**7602-7614.

361. **Zhang, X., K. Wu, D. Wang, X. Yue, D. Song, Y. Zhu, and J. Wu.** 2007. Nucleocapsid protein of SARS-CoV activates interleukin-6 expression through cellular transcription factor NF-kappaB. Virology **365:**324-335.

362. **Liao, Y., X. Wang, M. Huang, J. P. Tam, and D. X. Liu.** 2011. Regulation of the p38 mitogen-activated protein kinase and dual-specificity phosphatase 1 feedback loop modulates the induction of interleukin 6 and 8 in cells infected with coronavirus infectious bronchitis virus. Virology **420:**106-116.

363. **Banerjee, S., K. Narayanan, T. Mizutani, and S. Makino.** 2002. Murine coronavirus replication-induced p38 mitogen-activated protein kinase activation promotes interleukin-6 production and virus replication in cultured cells. J. Virol. **76:**5937-5948.

364. **Oostra, M., E. G. te Lintelo, M. Deijs, M. H. Verheije, P. J. Rottier, and C. A. de Haan.** 2007. Localization and membrane topology of coronavirus nonstructural protein 4: involvement of the early secretory pathway in replication. J. Virol. **81:**12323-12336.

365. **Verheije, M. H., M. Raaben, M. Mari, E. G. Te Lintelo, F. Reggiori, F. J. van Kuppeveld, P. J. Rottier, and C. A. de Haan.** 2008. Mouse hepatitis coronavirus RNA replication depends on GBF1-mediated ARF1 activation. PLoS Pathog. **4:**e1000088.

366. **Neuman, B. W., J. S. Joseph, K. S. Saikatendu, P. Serrano, A. Chatterjee, M. A. Johnson, L. Liao, J. P. Klaus**, *et al*. 2008. Proteomics analysis unravels the functional repertoire of coronavirus nonstructural protein 3. J. Virol. **82:**5279-5294.

367. **Belov, G. A., N. Altan-Bonnet, G. Kovtunovych, C. L. Jackson, J. Lippincott-Schwartz, and E. Ehrenfeld.** 2007. Hijacking components of the cellular secretory pathway for replication of poliovirus RNA. J. Virol. **81:**558-567.

368. **Belov, G. A., M. H. Fogg, and E. Ehrenfeld.** 2005. Poliovirus proteins induce membrane association of GTPase ADP-ribosylation factor. J. Virol. **79:**7207-7216.

369. **Gazina, E. V., J. M. Mackenzie, R. J. Gorrell, and D. A. Anderson.** 2002. Differential requirements for COPI coats in formation of replication complexes among three genera of Picornaviridae. J. Virol. **76:**11113-11122.

370. **Wang, J., Z. Wu, and Q. Jin.** 2012. COPI Is Required for Enterovirus 71 Replication. PLoS One **7:**e38035.

371. **van der Linden, L., H. M. van der Schaar, K. H. Lanke, J. Neyts, and F. J. van Kuppeveld.** 2010. Differential effects of the putative GBF1 inhibitors Golgicide A and AG1478 on enterovirus replication. J. Virol. **84:**7535-7542.

372. **Cureton, D. K., R. Burdeinick-Kerr, and S. P. Whelan.** 2012. Genetic inactivation of COPI coatomer separately inhibits vesicular stomatitis virus entry and gene expression. J. Virol. **86:**655-666.

373. **Cherry, S., A. Kunte, H. Wang, C. Coyne, R. B. Rawson, and N. Perrimon.** 2006. COPI activity coupled with fatty acid biosynthesis is required for viral replication. PLoS Pathog. **2:**e102.

374. **Konig, R., S. Stertz, Y. Zhou, A. Inoue, H. H. Hoffmann, S. Bhattacharyya, J. G. Alamares, D. M. Tscherne**, *et al*. 2010. Human host factors required for influenza virus replication. Nature **463:**813-817.

375. **He, D., C. Overend, J. Ambrogio, R. J. Maganti, M. J. Grubman, and A. E. Garmendia.** 2011. Marked differences between MARC-145 cells and swine alveolar macrophages in IFNbeta-induced activation of antiviral state against PRRSV. Vet. Immunol. Immunopathol. **139:**57-60.

376. **Rowland, R. R., B. Robinson, J. Stefanick, T. S. Kim, L. Guanghua, S. R. Lawson, and D. A. Benfield.** 2001. Inhibition of porcine reproductive and respiratory syndrome virus by interferon-gamma and recovery of virus replication with 2-aminopurine. Arch. Virol. **146:**539-555.

377. **Krahling, V., D. A. Stein, M. Spiegel, F. Weber, and E. Muhlberger.** 2009. Severe acute respiratory syndrome coronavirus triggers apoptosis via protein kinase R but is resistant to its antiviral activity. J. Virol. **83:**2298-2309.

378. **Woo, P. C., M. Wang, S. K. Lau, H. Xu, R. W. Poon, R. Guo, B. H. Wong, K. Gao**, *et al*. 2007. Comparative analysis of twelve genomes of three novel group 2c and group 2d coronaviruses reveals unique group and subgroup features. J. Virol. **81:**1574-1585.

379. **Vijaykrishna, D., G. J. Smith, J. X. Zhang, J. S. Peiris, H. Chen, and Y. Guan.** 2007. Evolutionary insights into the ecology of coronaviruses. J. Virol. **81:**4012-4020.

380. **Fouchier, R. A., N. G. Hartwig, T. M. Bestebroer, B. Niemeyer, J. C. de Jong, J. H. Simon, and A. D. Osterhaus.** 2004. A previously undescribed coronavirus associated with respiratory disease in humans. Proc. Natl. Acad. Sci. USA **101:**6212-6216.

381. **Raj, V. S., H. Mou, S. L. Smits, D. H. Dekkers, M. A. Muller, R. Dijkman, D. Muth, J. A. Demmers**, *et al*. 2013. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature **495:**251-254.

382. **Randall, R. E., and S. Goodbourn.** 2008. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J. Gen. Virol. **89:**1-47.

383. **Versteeg, G. A., P. J. Bredenbeek, S. H. van den Worm, and W. J. Spaan.** 2007. Group 2 coronaviruses prevent immediate early interferon induction by protection of viral RNA from host cell recognition. Virology **361:**18-26.

384. **Sims, A. C., S. C. Tilton, V. D. Menachery, L. E. Gralinski, A. Schafer, M. M. Matzke, B. J. Webb-Robertson, J. Chang**, *et al*. 2013. Release of severe acute respiratory syndrome coronavirus nuclear import block enhances host transcription in human lung cells. J Virol **87:**3885-3902.

385. **Yoshikawa, T., T. E. Hill, N. Yoshikawa, V. L. Popov, C. L. Galindo, H. R. Garner, C. J. Peters, and C. T. Tseng.** 2010. Dynamic innate immune responses of human bronchial epithelial cells to severe acute respiratory syndrome-associated coronavirus infection. PLoS One **5:**e8729.

386. **Zeng, F. Y., C. W. Chan, M. N. Chan, J. D. Chen, K. Y. Chow, C. C. Hon, K. H. Hui, J. Li**, *et al*. 2003. The complete genome sequence of severe acute respiratory syndrome coronavirus strain HKU-39849 (HK-39). Exp. Biol. Med. **228:**866-873.

387. **Weber, F., V. Wagner, S. B. Rasmussen, R. Hartmann, and S. R. Paludan.** 2006. Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses. J. Virol. **80:**5059-5064.

388. **Belouzard, S., J. K. Millet, B. N. Licitra, and G. R. Whittaker.** 2012. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses **4:**1011-1033.

389. **Snijder, E. J., P. J. Bredenbeek, J. C. Dobbe, V. Thiel, J. Ziebuhr, L. L. Poon, Y. Guan, M. Rozanov**, *et al*. 2003. Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J. Mol. Biol. **331:**991-1004.

390. **Vijgen, L., E. Keyaerts, E. Moes, I. Thoelen, E. Wollants, P. Lemey, A. M. Vandamme, and M. Van Ranst.** 2005. Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event. J. Virol. **79:**1595-1604.

391. **Pfefferle, S., S. Oppong, J. F. Drexler, F. Gloza-Rausch, A. Ipsen, A. Seebens, M. A. Muller, A. Annan**, *et al*. 2009. Distant relatives of severe acute respiratory syndrome coronavirus and close relatives of human coronavirus 229E in bats, Ghana. Emerg. Infect. Dis. **15:**1377-1384.

392. **Cameron, M. J., A. A. Kelvin, A. J. Leon, C. M. Cameron, L. Ran, L. Xu, Y. K. Chu, A. Danesh**, *et al*. 2012. Lack of innate interferon responses during SARS coronavirus infection in a vaccination and reinfection ferret model. PLoS One **7:**e45842.

393. **Roth-Cross, J. K., L. Martinez-Sobrido, E. P. Scott, A. Garcia-Sastre, and S. R. Weiss.** 2007. Inhibition of the alpha/beta interferon response by mouse hepatitis virus at multiple levels. J. Virol. **81:**7189-7199.
394. **Cervantes-Barragan, L., R. Zust, F. Weber, M. Spiegel, K. S. Lang, S. Akira, V. Thiel, and B. Ludewig.** 2007. Control of coronavirus infection through plasmacytoid dendritic-cell-derived type I interferon. Blood **109:**1131-1137.
395. **Kindler, E., H. R. Jonsdottir, D. Muth, O. J. Hamming, R. Hartmann, R. Rodriguez, R. Geffers, R. A. Fouchier**, *et al*. 2013. Efficient Replication of the Novel Human Betacoronavirus EMC on Primary Human Epithelium Highlights Its Zoonotic Potential. MBio **4:**e00611-00612.
396. **Rose, K. M., R. Elliott, L. Martinez-Sobrido, A. Garcia-Sastre, and S. R. Weiss.** 2010. Murine coronavirus delays expression of a subset of interferon-stimulated genes. J. Virol. **84:**5656-5669.
397. **Bergman, S. J., M. C. Ferguson, and C. Santanello.** 2011. Interferons as therapeutic agents for infectious diseases. Infect. Dis. Clin. North. Am. **25:**819-834.
398. **Breban, R., J. Riou, and A. Fontanet.** 2013. Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk. Lancet.
399. **Roberts, A., E. W. Lamirande, L. Vogel, J. P. Jackson, C. D. Paddock, J. Guarner, S. R. Zaki, T. Sheahan**, *et al*. 2008. Animal models and vaccines for SARS-CoV infection. Virus Res. **133:**20-32.
400. **Martin, J. E., M. K. Louder, L. A. Holman, I. J. Gordon, M. E. Enama, B. D. Larkin, C. A. Andrews, L. Vogel**, *et al*. 2008. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine **26:**6338-6343.
401. **Hopkins, A. L., and C. R. Groom.** 2002. The druggable genome. Nat. Rev. Drug Discov. **1:**727-730.
402. **Bienz, K., D. Egger, T. Pfister, and M. Troxler.** 1992. Structural and functional characterization of the poliovirus replication complex. J. Virol. **66:**2740-2747.
403. **Zebovitz, E., J. K. Leong, and S. C. Doughty.** 1974. Involvement of the host cell nuclear envelope membranes in the replication of Japanese encephalitis virus. Infect. Immun. **10:**204-211.
404. **Quinkert, D., R. Bartenschlager, and V. Lohmann.** 2005. Quantitative analysis of the hepatitis C virus replication complex. J. Virol. **79:**13594-13605.
405. **Ahlquist, P., S. X. Wu, P. Kaesberg, C. C. Kao, R. Quadt, W. DeJong, and R. Hershberger.** 1994. Protein-protein interactions and glycerophospholipids in bromovirus and nodavirus RNA replication. Arch. Virol. Suppl. **9:**135-145.
406. **Kovalev, N., J. Pogany, and P. D. Nagy.** 2012. A Co-Opted DEAD-Box RNA helicase enhances tombusvirus plus-strand synthesis. PLoS Pathog. **8:**e1002537.
407. **Rodriguez, P. L., and L. Carrasco.** 1992. Gliotoxin: inhibitor of poliovirus RNA synthesis that blocks the viral RNA polymerase 3Dpol. J. Virol. **66:**1971-1976.
408. **Gerber, L., T. M. Welzel, and S. Zeuzem.** 2013. New therapeutic strategies in HCV: polymerase inhibitors. Liver Int. **33 Suppl 1:**85-92.
409. **Tsai, C. H., P. Y. Lee, V. Stollar, and M. L. Li.** 2006. Antiviral therapy targeting viral polymerase. Curr. Pharm. Des. **12:**1339-1355.
410. **Law, G. L., M. J. Korth, A. G. Benecke, and M. G. Katze.** 2013. Systems virology: host-directed approaches to viral pathogenesis and drug targeting. Nat. Rev. Microbiol. **11:**455-466.
411. **Johnson, S. A., and T. Hunter.** 2005. Kinomics: methods for deciphering the kinome. Nat. Methods **2:**17-25.
412. **Dar, A. C., and K. M. Shokat.** 2011. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. Annu. Rev. Biochem. **80:**769-795.
413. **Schang, L. M.** 2011. Cellular Protein Kinases as Antiviral Targets, p. 305-347. In B. Klebl, G. Müller, and M. Hamacher (ed.), Protein Kinases as Drug Targets. Wiley-VCH Verlag GmbH & Co. KGaA.

414. **Lupberger, J., M. B. Zeisel, F. Xiao, C. Thumann, I. Fofana, L. Zona, C. Davis, C. J. Mee**, *et al*. 2011. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat. Med. **17:**589-595.

415. **Moser, T. S., R. G. Jones, C. B. Thompson, C. B. Coyne, and S. Cherry.** 2010. A kinome RNAi screen identified AMPK as promoting poxvirus entry through the control of actin dynamics. PLoS Pathog. **6:**e1000954.

416. **Song, S., J. Bi, D. Wang, L. Fang, L. Zhang, F. Li, H. Chen, and S. Xiao.** 2013. Porcine reproductive and respiratory syndrome virus infection activates IL-10 production through NF-kappaB and p38 MAPK pathways in porcine alveolar macrophages. Dev. Comp. Immunol. **39:**265-272.

417. **Josset, L., V. D. Menachery, L. E. Gralinski, S. Agnihothram, P. Sova, V. S. Carter, B. L. Yount, R. L. Graham**, *et al*. 2013. Cell Host Response to Infection with Novel Human Coronavirus EMC Predicts Potential Antivirals and Important Differences with SARS Coronavirus. MBio **4**.

418. **Wannee, K. F., A. H. De Wilde, M. Rabelink, R. Hoeben, J. J. Goeman, P. ten Dijke, E. J. Snijder, M. Kikkert, and M. J. van Hemert.** 2013. Kinome-targeted siRNA library screening identifies common cellular factors and signaling pathways influencing the replication of distantly related nidoviruses. Manuscript in Preparation.

419. **Novina, C. D., and P. A. Sharp.** 2004. The RNAi revolution. Nature **430:**161-164.

420. **Bushman, F. D., N. Malani, J. Fernandes, I. D'Orso, G. Cagney, T. L. Diamond, H. Zhou, D. J. Hazuda**, *et al*. 2009. Host cell factors in HIV replication: meta-analysis of genome-wide studies. PLoS Pathog. **5:**e1000437.

421. **Jackson, A. L., and P. S. Linsley.** 2010. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat. Rev. Drug Discov. **9:**57-67.

422. **Echeverri, C. J., P. A. Beachy, B. Baum, M. Boutros, F. Buchholz, S. K. Chanda, J. Downward, J. Ellenberg**, *et al*. 2006. Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat. Methods **3:**777-779.

423. **Dancourt, J., and C. Barlowe.** 2010. Protein sorting receptors in the early secretory pathway. Annu. Rev. Biochem. **79:**777-802.

424. **Bethune, J., F. Wieland, and J. Moelleken.** 2006. COPI-mediated transport. J. Membr. Biol. **211:**65-79.

425. **Brass, A. L., D. M. Dykxhoorn, Y. Benita, N. Yan, A. Engelman, R. J. Xavier, J. Lieberman, and S. J. Elledge.** 2008. Identification of host proteins required for HIV infection through a functional genomic screen. Science **319:**921-926.

426. **Tanaka, Y., Y. Sato, and T. Sasaki.** 2013. Suppression of coronavirus replication by cyclophilin inhibitors. Viruses **5:**1250-1260.

427. **Gething, M. J., and J. Sambrook.** 1992. Protein folding in the cell. Nature **355:**33-45.

428. **Schinzel, A. C., O. Takeuchi, Z. Huang, J. K. Fisher, Z. Zhou, J. Rubens, C. Hetz, N. N. Danial**, *et al*. 2005. Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia. Proc. Natl. Acad. Sci. USA **102:**12005-12010.

429. **Teigelkamp, S., T. Achsel, C. Mundt, S. F. Gothel, U. Cronshagen, W. S. Lane, M. Marahiel, and R. Luhrmann.** 1998. The 20kD protein of human [U4/U6.U5] tri-snRNPs is a novel cyclophilin that forms a complex with the U4/U6-specific 60kD and 90kD proteins. RNA **4:**127-141.

430. **Horowitz, D. S., E. J. Lee, S. A. Mabon, and T. Misteli.** 2002. A cyclophilin functions in pre-mRNA splicing. EMBO J. **21:**470-480.

431. **Steinbach, W. J., J. L. Reedy, R. A. Cramer, Jr., J. R. Perfect, and J. Heitman.** 2007. Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. Nature reviews. Microbiology **5:**418-430.

432. **Wainberg, M. A., A. Dascal, N. Blain, L. Fitz-Gibbon, F. Boulerice, K. Numazaki, and M. Tremblay.** 1988. The effect of cyclosporine A on infection of susceptible cells by human immunodeficiency virus type 1. Blood **72:**1904-1910.

433. **Montano-Loza, A. J., S. Wasilenko, J. Bintner, and A. L. Mason.** 2010. Cyclosporine A inhibits *in vitro* replication of betaretrovirus associated with primary biliary cirrhosis. Liver Int. **30:**871-877.

434. **Luban, J., K. L. Bossolt, E. K. Franke, G. V. Kalpana, and S. P. Goff.** 1993. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell **73:**1067-1078.

435. **Yang, F., J. M. Robotham, H. B. Nelson, A. Irsigler, R. Kenworthy, and H. Tang.** 2008. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance *in vitro*. J. Virol. **82:**5269-5278.

436. **http://www.clinicaltrials.gov/**

437. **Fischer, G., P. Gallay, and S. Hopkins.** 2010. Cyclophilin inhibitors for the treatment of HCV infection. Curr. Opin. Investig. Drugs **11:**911-918.

438. **Liu, Z., J. M. Robida, S. Chinnaswamy, G. Yi, J. M. Robotham, H. B. Nelson, A. Irsigler, C. C. Kao, and H. Tang.** 2009. Mutations in the hepatitis C virus polymerase that increase RNA binding can confer resistance to cyclosporine A. Hepatology **50:**25-33.

439. **Carbajo-Lozoya, J., M. A. Muller, S. Kallies, V. Thiel, C. Drosten, and A. von Brunn.** 2012. Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506. Virus Res. **165:**112-117.

440. **McHutchison, J. G., E. J. Lawitz, M. L. Shiffman, A. J. Muir, G. W. Galler, J. McCone, L. M. Nyberg, W. M. Lee**, *et al*. 2009. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. **361:**580-593.

441. **Manns, M. P., J. G. McHutchison, S. C. Gordon, V. K. Rustgi, M. Shiffman, R. Reindollar, Z. D. Goodman, K. Koury**, *et al*. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet **358:**958-965.

442. **Fried, M. W., M. L. Shiffman, K. R. Reddy, C. Smith, G. Marinos, F. L. Goncales, Jr., D. Haussinger, M. Diago**, *et al*. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. **347:**975-982.

443. **McHutchison, J. G., M. P. Manns, A. J. Muir, N. A. Terrault, I. M. Jacobson, N. H. Afdhal, E. J. Heathcote, S. Zeuzem**, *et al*. 2010. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. **362:**1292-1303.

444. **Flisiak, R., J. Jaroszewicz, I. Flisiak, and T. Lapinski.** 2012. Update on alisporivir in treatment of viral hepatitis C. Expert Opin Investig Drugs **21:**375-382.

445. **Chan-Yeung, M., and R. H. Xu.** 2003. SARS: epidemiology. Respirology **8 Suppl:**S9-14.

446. **Roberts, A., D. Deming, C. D. Paddock, A. Cheng, B. Yount, L. Vogel, B. D. Herman, T. Sheahan**, *et al*. 2007. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog. **3:**e5.

447. **McCray, P. B., Jr., L. Pewe, C. Wohlford-Lenane, M. Hickey, L. Manzel, L. Shi, J. Netland, H. P. Jia**, *et al*. 2007. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J. Virol. **81:**813-821.

448. **Munster, V. J., E. de Wit, and H. Feldmann.** 2013. Pneumonia from human coronavirus in a macaque model. N. Engl. J. Med. **368:**1560-1562.

449. **Madrid, P. B., S. Chopra, I. D. Manger, L. Gilfillan, T. R. Keepers, A. C. Shurtleff, C. E. Green, L. V. Iyer**, *et al*. 2013. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One **8:**e60579.

450. **Falzarano, D., E. de Wit, C. Martellaro, J. Callison, V. J. Munster, and H. Feldmann.** 2013. Inhibition of novel beta coronavirus replication by a combination of interferon-alpha2b and ribavirin. Sci. Rep. **3:**1686.

451. **Chan, R. W., M. C. Chan, S. Agnihothram, L. L. Chan, D. I. Kuok, J. H. Fong, Y. Guan, L. L. Poon**, *et al*. 2013. Tropism and innate immune responses of the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures. J. Virol.

452. **Zielecki, F., M. Weber, M. Eickmann, L. Spiegelberg, A. M. Zaki, M. Matrosovich, S. Becker, and F. Weber.** 2013. Human cell tropism and innate immune system interactions of human respiratory coronavirus EMC compared to those of severe acute respiratory syndrome coronavirus. J. Virol. **87:**5300-5304.